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ABSTRACT 
Nucleobindins are a class of secreted, multi-domain Ca2+ binding proteins that 
interact with nucleic acids. Two nucleobindins, nucleobindin-1 (NUCB1) and 
nucleobindin-2 (NUCB2) have been identified so far. In 2006, nesfatin-1, an 82 amino 
acid peptide encoded in NUCB2 was discovered. Nesfatin-1 is an anorexigenic and 
insulinotropic peptide found abundantly in hypothalamus, pancreas and stomach. Meal 
responsive insulin secretion is regulated by glucagon like peptide-1 (GLP-1), glucose 
dependent insulinotropic polypeptide (GIP), peptide YY (PYY) and cholecystokinin (CCK) 
secreted by intestinal mucosal cells. Since both nesfatin-1 and intestinal hormones 
modulate insulin secretion, nesfatin-1 could regulate intestinal hormones to elicit its 
insulinotropic action. Nucleobindin-1 primarily regulates Ca2+ homeostasis. Like NUCB2, 
NUCB1 is also present in the pancreas, stomach, intestine and pituitary. NUCB2 has a 
high similarity (62% in humans) to NUCB1. Both proteins also retain their prohormone 
convertase cleavage sites. However, no information exists on whether NUCB1 encodes 
bioactive peptides. The fact that NUCB1 is a secreted protein suggests an endocrine 
function for NUCB1 and/or its encoded peptide. This research hypothesizes that nesfatin-
1 is enterotropic, and NUCB1 encodes an insulinotropic nesfatin-1-like peptide (NLP). 
Nesfatin-1 protein expression was found in STC-1 cells and it co-localized GLP-1, GIP, 
CCK and PYY in mouse enteroendocrine cells. Treatment of STC-1 cells with nesfatin-1 
stimulated GLP-1, GIP, CCK mRNA expression and protein secretion, while opposite 
effects were found for PYY. In silico analysis of the NUCB1 amino acid sequence found 
a 77 amino acid NLP. Mouse pancreatic islets and MIN6 cells express NUCB1 mRNA 
and protein. NUCB1 was co-localized with insulin in mouse pancreatic islets. While 
treatment of cells with synthetic NLP increased preproinsulin mRNA expression and 
secretion, a scrambled peptide based on NLP was ineffective, indicating that the specific 
amino acid sequence is crucial for its insulinotropic action. Overall, the data presented 
supports the hypotheses. The studies reaffirm NUCB2 expression in intestine and provide 
the first set of evidence for nesfatin-1 regulation of enteric hormones. It also found a novel 
NUCB1 encoded insulinotropic NLP that could elicit other functions of nesfatin-1.  
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CHAPTER 1  
INTRODUCTION 
1.1. GENERAL INTRODUCTION 
The prevalence of metabolic diseases is reaching pandemic proportions 
worldwide, of which obesity and diabetes are the primary diseases of concern. In 2010, 
more than 285 million people worldwide had diabetes [1]. This estimate is 67% higher 
than those predicted in 2000 and with this trend, 439 million people worldwide will have 
diabetes by 2030. Since 2010, efforts are underway to combat the costs resulting from 
these debilitating metabolic complications. In the majority of cases of diabetes and 
obesity, the defects lie in glucose metabolism and energy homeostasis. Several lines of 
research are in progress, including the use of naturally occurring hormones to treat 
diabetes and obesity [2-4]. In this regard, the role of intestinal hormones in regulating 
glucose and energy homeostasis is well reported. Some examples of such hormones 
include the incretins glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic 
polypeptide (GIP), peptide YY (PYY), leptin, orexin, cholecystokinin (CCK), amylin and 
oxyntomodulin. All these hormones modulate insulin, which is secreted in a meal 
responsive manner [5-8]. In addition to these peptides, a recent addition to the growing 
list of pancreatic islet beta cell endocrine modulators is nesfatin-1 [9]. 
 Nesfatin-1 (NEFA/nucleobindin-2 Encoded Satiety and FAT Influencing proteIN-1) 
is a recently identified 82 amino acid anorexigenic (food intake inhibitory) peptide that is 
derived from the post-translational cleavage of its secreted precursor peptide 
nucleobindin-2 (NUCB2) at its N-terminal by prohormone convertases [9]. Plasma 
nesfatin-1 concentrations are inversely correlated with glucose levels in rats and diabetic 
(T1D and T2D) humans [10, 11]. Our research group for the first time showed that 
nesfatin-1 and insulin are co-localized in the β cells [12] of pancreatic islets and its 
stimulatory role in insulin secretion [5, 13], and glucose homeostasis [13]. Since its 
discovery in 2006, nesfatin-1 has emerged as a multifunctional peptide having a variety 
of tissue-specific functions. Besides hypothalamic feeding centers and endocrine 
pancreas, nesfatin-1 was reported in rat gastric oxyntic mucosa [14] and was found to be 
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co-secreted from distinct cytoplasmic vesicles in ghrelin producing X/A like cells. Our 
research recently determined that NUCB2 and nesfatin-1 are expressed in the small and 
large intestines of mice [15]. Previous research has shown that intestinal hormones GLP-
1, PYY, GIP and CCK modulate insulin secretion [6-8, 16]. Nesfatin-1, similar to these 
intestinal hormones, has a crucial role in modulating insulin secretion [5, 12, 13]. In 
addition to its insulinotropic actions, does nesfatin-1 also modulate intestinal hormones 
that regulate insulin release? The main focus of Chapter 2 of this thesis is to address this 
question. Maintenance of insulin secretion is crucial in vivo as insulin stimulates glucose 
uptake by cells, thereby regulating glucose homeostasis. Insulinotropic peptides i.e. 
peptides that increase insulin secretion are therefore much in focus for their therapeutic 
use in diabetes treatment. Nesfatin-1, as an insulinotropic peptide, is also pursued as a 
therapeutic target for diabetes.  
The third chapter of this thesis aims to investigate whether NUCB1 encodes a 
nesfatin-1-like peptide (NLP) and whether NLP has insulinotropic action similar to 
nesfatin-1. This is crucial, as no information exists regarding NUCB1 encoded 
insulinotropic peptide, although NUCB1 was identified more than a decade earlier to 
nesfatin-1. Is NUCB1 also a precursor of an insulinotropic peptide? NUCB1 is a 55 KDa 
multi-domain protein first discovered in cultured supernatant of a B lymphocyte cell line 
identified from mice prone to systemic lupus erythematosus, an autoimmune disorder 
[17]. It was identified as a golgi resident protein [18], secreted protein [19] and a nuclear 
protein [20]. Previous studies have shown that the secreted extracellular NUCB1 
contributes to matrix maturation in bones [21]. NUCB1 plays a crucial role in Ca2+ 
homeostasis [22] and was reported to interact with G proteins [22] and cyclooxygenases 
[23]. These studies indicate the important role of NUCB1 in multiple cellular processes. 
The nucleobindin genes (both NUCB1 and NUCB2) will be addressed in uppercase 
italicized letters, to distinguish from NUCB1 and NUCB2 proteins (uppercase non-
italicized), in rest of the thesis. Given the cytoplasmic location of NUCB1 and that it is 
secreted is indicative that it or its encoded peptides could have endocrine functions. 
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1.2. LITERATURE REVIEW 
1.2.1. Energy Metabolism and Type 2 Diabetes Mellitus 
Humans obtain energy from three classes of fuels: carbohydrates, lipids and 
proteins. Energy metabolism is the process of generating adenosine triphosphate (ATP) 
from these nutrients. It is comprised of linked pathways that function either in the presence 
or absence of oxygen. Typical aerobic metabolism will convert one molecule of glucose 
to 30-32 ATP molecules [24]. The three classes of energy rich fuels are acquired by food 
ingestion. Based on the nature of the ingested food, the percentage of energy fuels in 
them varies. The digestion of food in the alimentary tract and its subsequent absorption 
in blood stream makes it possible for cells and tissues to transform the chemical energy 
generated into useful work. Energy intake in the form of food, and energy expenditure in 
the form of cellular energy metabolism and exercise are precisely coupled over longer 
intervals. In healthy adults, this tight balance between intake and expenditure results in 
energy homeostasis and stable body fat reserves [25]. 
Amongst carbohydrate fuels, glucose is a major energy source for cells in the body. 
Glucose in cells is crucial for its proliferation, growth and survival. Therefore, maintenance 
of glucose levels in blood is an essential physiological process [26]. Insulin is a major 
peptide hormone secreted by β cells in the pancreas to regulate blood glucose levels. An 
elevation in blood glucose level during feeding stimulates insulin release, resulting in the 
uptake of glucose into skeletal muscles and adipose tissues. Diabetes or diabetes 
mellitus is a complex metabolic disease characterized by several metabolic abnormalities, 
especially elevated blood glucose levels over an extended period. The two major types 
of diabetes are type 1 diabetes (T1D) and type 2 diabetes (T2D). T1D primarily arises 
from the lack of insulin secretion from pancreatic islets. T2D is due to the loss of insulin 
sensitivity in glucose responsive cells, resulting in inhibition of glucose uptake in response 
to insulin [27]. The disruption of energy metabolism in T2D is well reported in literature 
with significant research focusing on the mechanism of insulin action and its receptor 
kinetics. 
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The onset of elevated blood glucose levels or hyperglycemia arises from three key 
defects: unregulated hepatic glucose production, diminished insulin secretion and 
impaired insulin action [28]. Insulin resistance is defined as the delayed response of cells 
to insulin. Human insulin receptor contains an two extracellular α subunit and two 
transmembrane β subunits [29]. The α subunits or the ligand-binding domain controls the 
activity of β subunits [30]. The gene coding for insulin receptor in mammals has 22 exons 
that generates two isoforms resulting from the alternative splicing of exon 11. The 
isoform-a called insulin receptor a (IRa) retains exon 11, whereas b-isoform (IRb) omits 
exon 11. In typical insulin responsive tissues including liver, adipose tissues and skeletal 
muscles the IRb expression is higher as it binds strongly to insulin. In contrast, the IRa 
binds with equal affinity to both insulin and insulin-like growth factor 2 (IGF2) and is 
expressed in the majority of fetal tissues and central nervous system (CNS) [31]. The 
insulin receptor resides in the plasma membrane and is activated by binding of insulin 
(ligand). Ligand binding increases the flexibility of the activation loop, which allows ATP 
to bind and autophosphorylate, thereby stabilizing the activation loop [32].  
In humans and other mammals, activated insulin receptor phosphorylates the 
tyrosine residues in intracellular insulin receptor substrates (IRS-1, IRS-2). Previous 
studies on transgenic mice suggests that the majority of insulin action is mediated through 
either IRS-1 or -2. Activation of the insulin receptor leads to the production of 
phosphatidylinositol triphosphate (PIP3) by phosphatidylinositol 3-kinase (PI3K). PIP3 
then recruits the phosphatidylinositol-dependent protein kinase 1 (PDK1) and protein 
kinase B (AKT) to the plasma membrane where AKT is activated by phosphorylation. AKT 
then phosphorylates a variety of proteins including glycogen synthase kinase 3β (GSK3β) 
in liver and AS160 protein which is involved in the translocation of the glucose transporter 
(GLUT4) [33]. The necessity of the IRS-PI3K-AKT-AS160 axis in insulin stimulated 
glucose uptake is well documented [34]. Depending on the tissue site, dysregulation of 
any of these signaling molecules, disrupts insulin signaling cascade resulting in sub-
optimal or lack of insulin responsiveness in cells. This progresses to hyperinsulinemia, 
glucose intolerance and insulin resistance seen in T2D. 
The pathophysiology of T2D is highly tissue specific. The skeletal muscles that 
contribute to 75% of glucose uptake is highly sensitive to blood glucose and plays a major 
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role in glucose homeostasis in patients with T2D [34]. As explained above IRS-1 and IRS-
2 are crucial in insulin responsive tissues like skeletal muscles. Studies have shown that 
IRS2 knockout mice progressively develop T2D with insulin resistance in skeletal muscles 
[35]. T2D subjects have impaired insulin stimulated tyrosine phosphorylation of IRS-1 in 
skeletal muscles. However, this was not due to a decreased protein expression of IRS-1. 
A similar impairment was observed at the level of PI3K in skeletal muscles of T2D 
subjects [34]. The dysregulation of the insulin receptor constitutes a common feature of 
insulin resistance in skeletal muscles of T2D patients. High levels of free fatty acids were 
known to contribute to insulin resistance by reducing the insulin stimulated glucose uptake 
via accumulation of lipids inside muscle cells [36]. T2D was also associated with impaired 
switching from fatty acid oxidation to glucose oxidation in response to insulin [37]. 
However, the cause of these derangements in skeletal muscles of T2D patients remains 
to be elucidated. 
In adipose tissues, the GLUT4 expression is downregulated in patients with T2D 
[38].  Owing to this, hyperglycemia associated with decreased glucose uptake cannot be 
explained in adipose tissues. The adipocyte-selective knockout of GLUT4 in mice resulted 
in insulin resistance similar to muscle selective knockout of GLUT4 [39]. Adipocyte 
GLUT4 deficiency results in the generation of circulating factors that are responsible for 
organ communication [40]. Of particular interest recently is the retinol-binding protein-4 
(RBP-4). Insulin resistant mice, obese and diabetic humans had increased RBP-4 protein 
levels. Also overexpression of RBP-4 gene or injection of RBP-4 recombinant protein 
caused insulin resistance in mice. Conversely RBP-4 knockout mice had enhanced 
insulin sensitivity [41]. Adipocytes secrete a wide array of factors that may alter insulin 
action in adipose tissue e.g. adiponectin, resistin, leptin and TNFα [42].  
T2D has been reported to have direct effects on the pancreatic β cells, contributing 
to apoptosis and reduction in mass and ability to compensate for insulin resistance [43]. 
A wide variety of mechanisms for these effects of T2D on pancreatic islets have been 
proposed in literature which includes endoplasmic reticulum stress [44], chronic 
hyperglycemia [45], chronic hyperlipidemia [46], oxidative stress [47] and inflammatory 
cytokines [48]. Reduced insulin sensitivity of β cells has been attributed to the early failure 
of insulin secretion in T2D pathogenesis [49]. However, many questions remain open on 
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the effect of T2D on β cells. What is the mechanism of β cell compensation in 
hyperinsulinemia? At which point in T2D pathogenesis this compensation fails? 
Nonetheless, the consensus in the literature is that the main adverse effects of T2D on β 
cells are its loss of insulin sensitivity and insulin secretion later in the disease as β cell 
mass decreases. 
An organ with the ability to absorb, store and produce glucose is liver. It maintains 
glucose and lipid homeostasis in the body. Owing to its role in maintaining glucose levels, 
it is a key target for insulin and its catabolic counterpart glucagon. Increased blood 
glucose causes release of insulin from β cells and this effect is amplified by the presence 
of FFA. Lack of insulin sensitivity and disrupted insulin action in liver has a significant 
contribution towards hyperglycemia and dyslipidemia [50]. Similar to skeletal muscles 
IRS-1 and -2 are complementary key players in liver, regulating insulin signaling, 
expression of genes in gluconeogenesis, glycogen synthesis and lipid metabolism [50]. 
Dysfunctional IRS in liver leads to postprandial hyperglycemia, increased hepatic glucose 
production both of which have a major contribution in the development of insulin 
resistance in T2D [51-53]. Liver specific IRS-2 knockout mice have T2D, increased 
adiposity, female infertility, insulin resistance in liver and skeletal muscles and lack of β 
cell compensation for peripheral insulin resistance [35, 54]. 
Above all these tissue specific contributions to T2D pathophysiology, it has a very 
strong genetic component to it. The lifetime risk of T2D is about 7% in people with a 
healthy medical history. However, the chances of T2D are as high as 40 and 70% for 
offspring of a single or double parent T2D respectively [55]. Twenty common genetic 
variants of T2D have been identified recently using linkage analysis, candidate gene 
approaches and by genome wide association studies (GWAS) [56]. The genetic mapping 
results showed that insulin sensitivity is related to eight candidate genes TCF7L2, 
KCNJ11, HHEX, SLC30A8, CDKAL1, CDKN2A/2B, IGF2BP2, and KCNQ; PPARG, 
glucose transport to CAPN10 gene and melanocortin receptor gene MC4R and FTO to 
obesity [56]. This explains the complex nature of T2D, due to multi-faceted genetic 
background and varied gene-environment interactions. These lead to defective insulin-
mediated glucose uptake, β cell dysfunction, dysregulation of adipocyte and liver. An 
overall state of dysregulated metabolism over time also causes extensive T2D related 
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complications in nearly all tissues and organs. Recent advances have led to many 
interesting animal models for studying T2D. This includes the ob/ob (spontaneous 
mutation in ob (obese) Lep (leptin) gene) [57] and db/db mouse (point mutation in db 
(diabetes) LEP-R (leptin receptor) gene) [58], Zucker fatty rats, Zucker diabetic fatty rat 
and obese rhesus monkey. Current research has focused on exploring the mechanism of 
pathogenesis of T2D using these animal models [59, 60]. 
1.2.2. Several Hormones Regulate Appetite and Energy Metabolism 
 As discussed in the previous section, energy homeostasis refers to two distinct 
processes in vivo: 1) the maintenance and regulation of readily available supply of energy 
metabolites in circulation; and 2) the regulation of adipose tissue mass that serves as a 
major energy store. Both these aspects are linked to eating, which eventually results in 
the entry of sufficient energy metabolites from the intestine into circulation. Meal size, to 
a large extent maintains the above two processes of energy homeostasis. Previous 
studies have shown that the total amount eaten correlates with the average meal size but 
not meal frequency [61]. Diluting the energy content of diet results in an immediate 
increase in meal size [62]. Diabetic rats that cannot metabolize glucose normally increase 
meal size rather than frequency [63]. The effect of meal size on two distinct parameters 
of energy homeostasis arises from two different classes of feedback signals. The first, 
described by Smith et al., [64] consists of negative feedback signals that are generated 
from the GI tract in response to nutrient stimuli. The primary effect of these signals is to 
produce satiation. Circulating energy metabolites and hormones that arise from organs 
such as liver, pancreas and adipose tissue and from nutrient absorption are the second 
class of feedback signals that act on “metabolic sensing neurons” in the CNS [65]. The 
current understanding is that the gastrointestinal nutrient signals and metabolic sensing 
neurons converge in the caudal brainstem that also regulates motor control of satiation. 
A variety of hormones have direct and/or indirect effects on feed intake and cellular 
energy metabolism. Leptin, the satiety hormone secreted from adipose cells, adiponectin 
secreted from adipose tissues that regulates glucose levels and fatty acid breakdown, 
amylin co-secreted with insulin from β cells that slows gastric emptying and promotes 
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satiety and oxyntomodulin secreted from the oxyntic cells in colon that suppresses 
appetite are few examples of such hormones.  
The GI tract over the years has evolved as a major endocrine organ in the body. 
Specialized enteroendocrine cells present here secrete a variety of peptides that act as 
short and long-term peripheral signals for regulation of feed intake and energy balance 
[66]. Upon release from the GI tract in response to an ingested meal, the enteric 
hormones modulate the brain orexigenic and/or anorexigenic neuropeptides either 
directly or through nervous signaling from periphery to brain, thereby regulating feed 
intake [67].  Since this thesis research focuses on four major peptides i.e. GLP-1, GIP, 
CCK and PYY primarily produced from the GI tract, literature review will be limited to 
these four intestinal hormones [68-70].  
During early 1900s, the concept of certain factors secreted from the intestinal 
mucosa in response to ingested nutrients that are capable of releasing substances from 
endocrine pancreas leading to a reduction in blood glucose levels was introduced [71]. 
The term “incretins” was then used to denote these glucose lowering factors derived from 
intestine [72]. With the advent of radioimmunoassay (RIA), it was shown that oral glucose 
administration is associated with a much greater increase in plasma insulin when 
compared to the same amount given intravenously [73]. This result further solidified the 
concept that intestinal insulinotropic factors exist. The phenomenon of intestinal factors 
enhancing insulin secretion is called the “incretin effect”, and it contributes to 
approximately 70% of insulin secretion in response to oral glucose. 
 The first described incretin hormone was isolated from the crude extracts of 
porcine small intestine and had the ability to inhibit gastric acid secretion in dogs. It was 
hence named gastric inhibitory polypeptide (GIP) [74]. However, studies using more 
purified extracts showed that GIP stimulates insulin secretion in animals and humans [75] 
even at a physiological dose, it was renamed as glucose dependent insulinotropic 
polypeptide (GIP). GIP is a 42 amino acid peptide secreted by the K-cells in the upper 
small intestine in response to carbohydrates and lipids. However, it was found that 
immunoneutralization of endogenous GIP activity attenuated but did not abolish the 
incretin effect in rodents and surgical resection of ileum in humans was associated with 
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diminished incretin activity, despite normal plasma GIP levels [76]. This observation led 
to the discovery of second incretin hormone, glucagon-like peptide-1 (GLP-1) after 
cloning and sequencing of the mammalian proglucagon cDNAs. Since, the proglucagon 
gene in addition to glucagon also encoded two other peptides that were 50% homologous 
to glucagon they were named glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-
2 (GLP-2). Of these, GLP-1 alone was insulinotropic. GLP-1 is a highly tissue-specific 
post-translational product of the proglucagon gene, secreted and released from the 
intestinal L cells in response to nutrients and glucose-stimulated insulin secretion (GSIS) 
[77]. GLP-1 and GIP are the only known incretin hormones and contribute in an additive 
manner towards the incretin effect.  
 The long arm of chromosome 2 encodes the proglucagon gene which has 6 exons 
and 5 introns, with the entire coding sequence of GLP-1 present within exon-4 [78]. The 
GLP-1 gene is predominantly expressed in pancreatic α cells, the L-cells of the intestine 
and neurons in the caudal brainstem and hypothalamus. The mRNA generated by the 
transcription of this gene is structurally identical in all of the above-mentioned three cells 
[77, 79]. There are similarities in proglucagon gene expression in α cells and the intestine. 
Similar to α cells, intracellular cAMP and activation of cAMP/PKA pathway is critical for 
intestinal proglucagon gene expression [80]. Increase in cAMP levels also upregulates 
proglucagon gene transcription by activation of PKA. Nutrient ingestion is a primary 
regulator of proglucagon expression in intestine [81]. Fasting decreases, whereas 
refeeding increases proglucagon expression in rat intestine [82]. Meals containing high 
levels of fibers and short chain fatty acids also increase its expression [83, 84]. Gastrin-
releasing peptide and GIP are also known to increases proglucagon mRNA expression 
in intestine. Overexpression of transcription factor Pax-6 via adenovirus in primary cells 
cultures of intestine, enhances the expression of proglucagon gene expression [85]. An 
opposite effect is seen in mice that express the dominant negative form of Pax-6, showing 
a reduction in proglucagon expression [86]. These studies show the importance of Pax-6 
in proglucagon expression in both pancreas and intestine. Transfection of rodent islets 
with human proglucagon promoter-reporter plasmids shows that the sequence within the 
first 6 kb of human proglucagon gene 5’-flanking region is required for its pancreas-
specific expression [87]. Subsequent cell transfection studies revealed a conserved 
 10 
 
region within intron 1 named “ECR3” that is critical for its expression in pancreatic islet α 
cells and intestine. These studies reveal that the human proglucagon gene uses a distinct 
set of transcription factors to specify tissue-specific proglucagon gene transcription. The 
proglucagon mRNA is translated into a single protein (180 amino acids) which then 
undergoes tissue-specific posttranslational processing yielding specific peptides in α 
cells, intestine and brain (Figure 1.1). Of several prohormone convertases (PC), PC 1/3 
and 2 alone were shown to be important in processing proglucagon [88].  
 
Figure 1.1. A depiction of the proglucagon gene, transcribed proglucagon mRNA and the 
translated protein. The protein is then post-translationally processed to glucagon (Gluc), 
glicentin-related polypeptide (GRPP), intervening peptide-1 (IP-1) and major proglucagon 
fragment (MPGF) in pancreas. In intestinal L cells and central nervous system the protein 
is processed into glicentin, oxyntomodulin (OXM), intervening peptide-2 (IP-2), GLP-1 
and GLP-2. 
GLP-1 is synthesized within and secreted by the L cells in the distal ileum and 
colon. The L cells are open type intestinal epithelial enteroendocrine cells. That is, they 
are in direct contact with luminal nutrients on the apical side and neural and vascular 
tissues through their basolateral side. Meal rich in fats and carbohydrates are primary 
physiologic stimuli for GLP-1 secretion in rodents [89]. GLP-1 secretion occurs in a 
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biphasic pattern with an early 10-15 minute phase and a longer 30-60 minute second 
phase in rats [90]. Multiple forms of GLP-1 in secretion includes GLP-1(1-37) and GLP-
1(1-36)NH2 which are inactive, GLP-1(7-37) and GLP-1(7-36)NH2 that are bioactive. In 
humans majority of GLP-1 in circulation is GLP-1(7-36) NH2 [91]. The half-life of bioactive 
GLP-1 in circulation is less than 2 minutes as it is rapidly inactivated by proteolytic enzyme 
dipeptidyl peptidase-4 (DPP-4) that cleaves GLP-1 at the penultimate alanine residue 
[92]. The central and peripheral administration of GLP-1 strongly stimulates insulin 
release. Intracerebroventricular administration of GLP-1 reduces food intake in rodents 
and its peripheral administration inhibits appetite in humans [93]. 
The GLP-1 receptor (GLP-1R) is a 7-transmembrane-spanning heterotrimeric G-
protein coupled receptor (GPCR) which acts as receptor for glucagon, GLP-2 and GIP 
[94]. In rodents and humans, a single GLP-1R that is structurally identical has been 
characterized in a wide variety of tissues ranging from pancreatic islets (α, β and δ cells), 
liver, heart, kidney, stomach, intestine, pituitary, skin, brainstem, nodose ganglion 
neurons and vagus nerves. In humans secretion of GLP-1 throughout the day strongly 
correlates with the release of insulin. The effect of GLP-1 on insulin secretion is strictly 
glucose-dependent and no effects on insulin secretion for glucose concentration below a 
certain threshold level (4.5 mmol/L) was observed. GLP-1 has also been shown to 
stimulate insulin gene transcription and all steps of insulin biosynthesis in isolated β-cells 
[8]. It stimulates β-cell proliferation and neogenesis from rat and human pancreatic duct 
[95]. GLP-1 inhibits glucagon secretion (glucagonostatic) in pancreatic islets. 
Administration of GLP-1 in T1D patients inhibited glucagon secretion and decreased 
blood glucose level suggesting that it suppresses the hepatic production of glucose 
induced by glucagon [96]. The inhibitory effects of GLP-1 are also extended to the GI tract 
wherein it slows down gastric emptying and glucose absorption [97]. This inhibitory role 
is crucial in pathological conditions like diabetes because they potentially reduce 
postprandial glucose excursions. The secretion of GLP-1 is impaired in patients with T2D. 
However, the insulinotropic response of GLP-1 and its glucagonostatic activity is 
preserved as in normal subjects [98]. A study involving a lizard, the gila monster 
(Heloderma suspectum), resulted in the isolation of exendin-4, a peptide that is a potent 
DPP-IV degradation-resistant agonist of the mammalian GLP-1 receptor [99]. This 
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analogue of GLP-1, under the trade name Byetta™, is currently commercially available 
in the United States as a therapeutic agent for T2D [100]. 
In rat hepatocytes and skeletal muscles, GLP-1 increases glucose incorporation 
and enhances insulin-stimulated glucose metabolism in 3T3 L1 adipocytes and primary 
rat adipocytes. GLP-1 stimulates cAMP production in isolated rat primary hepatocytes 
and exendin-4 improves insulin sensitivity and aids in reversal of hepatic steatosis in 
ob/ob mice [101]. GLP-1 and exendin-4, increases glycogen synthase activity in rat 
soleus muscles and human skeletal muscles. In addition, GLP-1 also has lipolytic effects 
in rat adipocytes and has both lipolytic and lipogenic actions in human adipocytes [102, 
103]. Intravenous administration of GLP-1R agonist increases systolic, diastolic, mean 
arterial pressure and heart rate in rodents. GLP-1 also exhibits cardioprotective effects in 
models of cardiac injury and failure [104]. In humans, a 72 hour GLP-1 perfusion in 
angioplasty and myocardial infarction patients improved their left ventricular function 
[105]. Despite all these tissue-specific biological actions of GLP-1, an ongoing question 
is whether these are solely due to its endocrine action as a circulating hormone or whether 
recruitment of CNS GLP-1R mediates some of peripheral actions of endogenous GLP-1? 
Also whether native GLP-1 exerts its metabolic actions (weight loss and decreased feed 
intake) by communicating with brain or by ascending neural pathways or in part by direct 
access to brain GLP-1R remains unclear. Recent trials have shown remarkable results 
using high molecular weight GLP-1R agonists. Studies using 4 structurally unique GLP-
1R analogues CJC113, CJC114, albiglutide and CNTO736 showed successful entry into 
brain showing their full range of actions, despite their large size. This includes, activation 
of neuronal c-Fos expression, inhibition of gastric emptying, reduction of food intake and 
weight loss with chronic administration [106-109]. 
The GIP gene in humans consists of 6 exons with the majority of GIP encoding 
sequences found in exon 3, being localized to the long arm of chromosome 17. GIP is 
expressed predominantly in stomach and intestinal K cells in rodents and humans. There 
is little information about the regulation of GIP gene expression. Recent studies stress 
the importance of the transcription factor Pdx-1 and that it could mediate the cell-specific 
GIP gene expression. Pdx-1 was also detected in the nucleus of the mouse K cells 
secreting GIP, and the number of intestinal GIP secreting cells is drastically reduced in 
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Pdx-1 -/- mice [110]. Chromatin immunoprecipitation in the same study also revealed Pdx-
1 binding to GIP promoter region and its overexpression in transfection assays increased 
the activity of GIP promoter/reporter gene constructs [110]. GIP is derived from a larger 
ProGIP prohormone precursor that encodes N-terminal peptide, GIP and C-terminal 
peptide (Figure 1.2). PC knockout mice study and overexpression of PC enzymes in vitro 
showed that mature 42 amino acid GIP is released from 153 amino acid ProGIP precursor 
via PC 1/3 posttranslational cleavage [111].  
 
Figure 1.2. Processing of mature GIP from the ProGIP gene. The precursor protein is 
post-translationally cleaved by PC 1/3 at a single arginine residue flanking the GIP mature 
peptide region. 
 GIP is synthesized and released from K cells in the duodenum and proximal 
jejunum [112]. Rather than the presence of nutrients, it is the rate of nutrient absorption 
that primarily stimulates GIP secretion. Thus, GIP secretion is reduced in patients with 
intestinal malabsorption or after administration of exogenous agents that reduce nutrient 
absorption [113]. There is a species-specific difference to the nutritional regulation of GIP 
secretion, as fat stimulates it in humans and carbohydrates are most effective in 
stimulating them in rodents and pigs. The half-life of intact bioactive GIP is 2 minutes in 
rodents [92] and 7 to 5 minutes in healthy human subjects and T2D patients [114]. Similar 
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to GLP-1, since GIP has an alanine residue in position 2, it is a target for DPP-4 mediated 
inactivation, which cleaves it into an active GIP (1-42) and GIP (3-42) that are inactive. 
However, intravenous infusion of GIP in humans found 40% bioactive GIP remains intact 
when compared to 20% active GLP-1. This shows that it is less susceptible to DPP-4 
cleavage in vivo than GLP-1 [92]. 
 GIP receptor (GIPR) is a 7-transmembrane spanning heterotrimeric GPCR similar 
to GLP-1R [115]. The human GIP receptor (GIPR) contains 14 exons and is localized in 
chromosome 19. GIPR is expressed in pancreas, small intestine, stomach, adipose 
tissue, adrenal cortex, heart, pituitary, testis, bone, spleen, thymus, lung, kidney and in 
several regions of the CNS. Relatively little is known on the factors regulating GIPR 
expression. However, GIPR mRNA and protein levels are reduced in the islets of diabetic 
rats, consistent with defective GIP action in diabetic animals and humans [116]. GIP 
exerts glucose-dependent stimulatory effect on insulin secretion in isolated perfused rat 
pancreas and humans [6]. GIP also upregulates insulin gene transcription and 
biosynthesis in β cells [117]. Elimination of GIPR signaling via GIPR knockout mice results 
in impaired oral glucose tolerance and a defective glucose stimulated insulin secretion 
[118]. Infusion of exogenous GIP into diabetic rats for 2 weeks reduces β cell apoptosis, 
by decreasing the expression of the pro-apoptotic bax gene [119]. GIP also reduces the 
expression of biochemical markers responsible for endoplasmic reticulum (ER) stress in 
cells of the islets, after inducing ER stress in vitro [120]. 
 GIP in the CNS has been shown to play a crucial role in neural progenitor cell 
proliferation and behavior modification, as transgenic mice that overexpress GIPR have 
enhanced sensorimotor co-ordination and increased memory compared to wild types 
[121]. Besides cerebral cortex, hippocampus and olfactory bulb in the CNS, GIPR is also 
expressed in isolated rat adipocytes and 3T3 L1 cells [122]. GIP has been reported to 
have lipogenic and lipolytic actions in vivo. It stimulates fatty acid synthesis and re-
esterification, increases insulin-stimulated incorporation of fatty acids into triglycerides 
and upregulates lipoprotein lipase synthesis [123]. On the other hand, GIPR -/- mice are 
resistant to diet induced obesity and have less adipocyte mass even after high fat diet 
feeding [124]. Leptin deficient ob/ob mice with GIPR knockout gain less weight and have 
improved glucose tolerance, insulin sensitivity and expend more energy than wild type 
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mice thereby preventing fat accumulation in adipocytes [124]. GIP increases bone mineral 
density in a rodent model of post-menopausal osteoporosis [125]. Subsequently GIPR 
knockout mice have reduced bone mass and size, altered bone turnover and abnormal 
bone microarchitecture. On the contrary, mice over-expressing GIP have greater bone 
mass than wild-type controls [126]. In stomach, GIP increases gastric acid secretion and 
upregulates specifically intestinal hexose transport [127]. It also attenuates glucagon 
stimulated hepatic glucose production, although the presence of GIPR in liver was not 
convincingly shown. The abnormal expression of GIPR in adrenocortical adenomas could 
contribute to the development of food-dependent Cushing’s syndrome [128]. The GIPR 
is also present in endothelial cells and increases intracellular Ca2+ in these cells [129]. 
Depending on the type of vascular bed involved GIP infusion can stimulate either 
vasoconstriction or vasodilation in dogs. This opposing effect is believed to be due to 
differential activation of GIP’s signal transduction pathways in distinct endothelial cell 
types. Besides all tissues discussed here, GIPR mRNA is also expressed in heart, testis 
and lung. However, the function of GIP on these tissues remains to be elucidated. 
 Cholecystokinin (CCK) is a peptide hormone secreted from the I-cells in the 
intestine. The action of this hormone was first characterized in 1973 [130]. CCK was the 
first gastrointestinal hormone found to act as a hunger suppressant. Upon nutrient 
stimulus, CCK from intestine stimulates pancreatic hormone secretion, bile secretion 
[131] and inhibits gastric emptying [132]. CCK levels in blood increases approximately 15 
minutes after meal initiation, with a half-life of 1-2 minutes in circulation [131]. There are 
several bioactive forms of CCK such as CCK-8, -22, -33 and -58 that differ in the number 
of amino acids. All forms are derived from a 95 amino acid precursor peptide pro-CCK 
[133] The predominant form is CCK-33 which is found in plasma and intestine [134]. CCK 
is also expressed in central and enteric nervous system specifically in the dorsomedial 
nucleus (DMN) and median eminence of the hypothalamus [135, 136]. 
 Two types of CCK receptors have been characterized, CCKA and CCKB. The 
CCKA receptor subtype predominates in the GI system, but occurs also in highly localized 
areas of the rat CNS, where it modulates feeding and dopamine-induced behavior [137, 
138]. CCKB receptor predominates the CNS and are involved in the modulation of 
anxiety, neuroleptic activity and arousal [138]. CCK is reported to reduce appetite. In rats, 
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administration of CCK-8 reduces meal size and duration while leaving water intake 
unchanged. Similar findings were also reported in humans, with the infusion of CCK-8 
reducing meal intake and initiating meal termination [139]. Recent evidences also 
suggests that when the stomach is distended, the satiety-inducing effect of CCK-8 is 
significantly increased, possibly involving a synergistic action [132]. Rats lacking CCKA 
expression present with high food intake, obesity and hyperglycemia [132]. However, this 
is not reiterated by the studies on knockout mice, as the data is not suggestive of any 
long-term effects on body weight [140]. CCKA receptors are expressed in the pancreas, 
nucleus of the solitary tract (NTS), afferent and efferent neurons of the vagus nerve and 
DMN in hypothalamus which are crucial centers for regulating food intake [141]. 
 In vitro studies have demonstrated that CCK causes insulin exocytosis [16] and 
promotes growth of pancreatic β cells [139]. CCK exerts a protective effect on β cells and 
islets of ob/ob mice. The islets from these mice expressed higher amounts of CCK 
compared to lean mice and helps modulate insulin expression by preventing cell death 
from stress-mediated pathways [142]. The action of CCK on pancreatic exocrine 
secretion is either direct via the receptors expressed on the pancreatic acinar cells, or 
indirect via receptors expressed on the vagal afferents, which when depolarized relays 
the signal through the efferent nerves in the pancreas. Two paradigms have emerged 
regarding the action of CCK on pancreatic secretion. 1) CCK could act directly on the 
neurons located in the dorsal motor nucleus of the vagus (DMV) [143] or 2) CCK could 
act simultaneously on the pancreatic stellate cells stimulating pancreatic exocrine 
secretion [144]. 
 The influence of exogenous CCK on reduction of food intake is dose-dependent 
in both rats and humans [130, 145]. Gastric and abdominal vagatomy abolished the 
satiety induced by CCK-8 administration peripherally, indicating that the CCKA receptors 
in the vagus nerve plays a crucial role in its regulation of feed intake [146]. CCK 
administered centrally also decreases food intake and the effects are potentiated by 
concomitant administration of leptin, indicating that CCK along with leptin could play an 
important role in long-term weight regulation [147]. Studies have evaluated the use of 
CCK as a treatment for obesity. Infusion of CCK for 6 days reduces ingested meal size 
by 44%. However, meal frequency is increased by 162% with no effect on body weight 
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[148]. Furthermore, 2 week intraperitoneal infusion of CCK resulted in development of 
tolerance for the peptide, thus having a lack of effect on feed intake or body weight [149]. 
The increase in postprandial CCK levels was high and quicker in lean individuals, possibly 
leading to an early occurrence of satiety, while in obese individuals, postprandial CCK 
levels remained higher for longer periods [150]. Postprandial CCK levels was also 
demonstrated to be sex-specific with females showing higher CCK levels than males 
[151]. 
PYY, like neuropeptide Y (NPY) and pancreatic polypeptide (PP), belongs to the 
“PP-fold” family of proteins. Similar to all PP fold family proteins, intracellular post-
translational C-terminal amidation of PYY in L cells of large intestine increases its half-life 
in circulation and is crucial for its biological activity. Endogenously PYY exists in two 
forms: PYY1-36 and PYY3-36 [152]. Similar to GLP-1, PYY1-36 is cleaved at the amino 
terminal by cell surface enzyme DPP-4 giving rise to PYY3-36, the predominant circulating 
form [153]. PYY is detected in low levels in stomach and the levels increases distally 
along small and large intestine, reaching highest levels in the cells of colon and rectum 
[154]. PYY is secreted from the L cells in proportion to feed intake and the circulating level 
is lowest in the fasting state. Plasma levels raise within 30 minutes post-prandially and 
plateaus within 1-2 hours, remaining elevated for 6 hours [155]. Among different types of 
nutrients, protein rich meals cause the greatest increase in PYY levels [156]. 
Administration of PYY3-36 reduces feed intake and weight gain in rodents [157-159]. 
Demonstration of PYY’s anorectic actions is highly dependent on full acclimatization of 
animals to handling and injection procedures as even mild stressors affects baseline 
feeding, making it difficult for anorectic agents to further suppress appetite. Intravenous 
administration of PYY reduces food intake in humans and was shown to be equally 
effective in normal and obese subjects [155]. The anorectic actions of PYY3-36 are 
mediated via arcuate nucleus (ARC) in the hypothalamus as the early gene marker, c-fos 
expression increases in this nucleus in response to peripheral PYY administration. There 
are conflicting results on the effect of PYY3-36 on propiomelanocortin (POMC) and 
AgRP/NPY neurons in ARC. Peripheral administration of PYY has been shown to 
decreases expression and release of NPY whilst activating POMC neurons [160]. 
However, reports have shown that PYY3-36 inhibits POMC neurons via postsynaptic Y2R 
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(Y2 receptor; PYY receptor) [161]. This was clarified by studies in POMC knockout mice, 
which maintained their anorectic response to peripheral PYY3-36 administration showing 
that POMC neurons are not critical for the anorectic response of PYY [162]. 
Both PYY1-36 and PYY3-36 exert their effect via neuropeptide family of receptors 
[162]. PYY1-36 binds with equal affinity to all Y receptors. However, PYY3-36 selectively 
binds with high affinity to Y2R subtype and its effect on food intake is mediated via this 
receptor [160]. This was further confirmed by studies using antagonists of Y2R that 
attenuated the anorectic effects of PYY3-36 [163]. Besides, PYY is present in myenteric 
nervous plexus neurons that innervate the GI tract and the Y2R has been identified on the 
vagus nerve [164]. Furthermore, total vagotomy or transectoning of brainstem-
hypothalamic pathways abolished PYY3-36 effect on food intake and ARC activation in 
rodents, suggesting a crucial role for vagus in appetite regulation [165]. PYY has been 
shown to have an effect on intestinal motility. Intra-arterial PYY administration in cats 
causes jejunal and colonic motility [166]. PYY also delays gastric emptying, decreases 
pancreatic secretions, and increases absorption of fluids and electrolytes from human 
ileum [167, 168]. More recently, it was shown that the acute effects of gastrointestinal 
bypass surgery on weight loss is lost in PYY knockout mice and that wild-type mice losing 
weight after surgery exhibit increased colonic PYY expression and circulating fasting PYY 
levels [169], highlighting the crucial role of PYY in mediating early weight loss in GI bypass 
surgery. 
Apart from the intestinal cells, PYY has been demonstrated to be localized in the 
pancreatic α cells [7]. Electron microscopy and immunohistochemistry studies have 
revealed that PYY and glucagon are co-stored in the secretory granules of α cells, 
suggesting a possible role as an intraislet regulatory peptide. Major studies so far have 
focused on the role of PYY in T1D, which results from sub-optimal levels of insulin 
secretion from the pancreatic islets. PYY inhibits stimulated insulin secretion under In vivo 
conditions in rat, dogs and mouse [7, 170, 171]. The number of rectal PYY cells in patients 
with T1D was found to be significantly higher than in healthy volunteers [172]. Also, the 
number of colonic PYY cells was reduced in non-obese diabetic (NOD) mice. However, 
no significant decrease in the cell number was observed in pre-diabetic NOD mice. 
Surprisingly, radioimmunoassay of tissue extracts showed lower concentrations of 
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colonic PYY cells in both pre-diabetic and diabetic mice [173]. Thus, it can be inferred 
that the synthesis of PYY decreases prior to the onset of diabetes, though the number of 
PYY cells remain unaffected. After the onset of diabetes, even the number of PYY cells 
declines, paving the way for PYY secretion as a possible biomarker for diabetes 
diagnosis. PYY has also been studied in two animal models of T2D, namely ob/ob and 
db/db obese diabetic mice. In ob/ob mice the number of colonic PYY cells and tissue 
concentrations of PYY were found to be lower than those in controls [174]. By contrast, 
the number of colonic PYY cells in db/db mice was reported to be higher than in controls 
[175]. This contradiction between the studies could be attributed to the difference in the 
duration of the diabetes in the ob/ob mice. 
Bertrand et al., [176] have reported a direct inhibitory effect of PYY on insulin 
secretion in rats. PYY caused a dose-dependent and sustained reduction of insulin 
secretion in the presence of 8.3 mM glucose. At a concentration of 10-9 M, PYY inhibits 
both phases of insulin secretion. In contrast, higher concentration of 10-8 M elicited a 
decrease in insulin output rate only during the first phase and no inhibitory effect was 
noted thereafter. Further studies on isolated islets showed that PYY at a concentration of 
10-7 M inhibited stimulated insulin secretion by 27% at a glucose concentration of 15 mM. 
However, this same concentration of PYY was ineffective in the presence of 3 mM 
glucose. The inhibitory effect of PYY on insulin secretion is comparable to the results 
previously observed with the neuropeptide Y in perfused rat pancreas [176, 177] although 
in contrast to NPY, PYY at 10-8 M inhibited insulin secretion only during the first 2 minutes, 
after which the inhibitory action disappeared. This might be due to an indirect action of 
PYY via stimulation of glucagon secretion. However, this can also be ruled out, since 
glucagon secretion was not increased by PYY at 10-8 M in the same study. It has been 
proposed that the inhibition of insulin secretion by PYY could be mediated via decrease 
in the pancreatic flow rate [178]. As reviewed in this section, the list of major hormones 
regulating appetite and energy metabolism includes but are not limited to GLP-1, GIP, 
CCK and PYY. A recent addition to this list is nesfatin-1. 
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1.2.3. Nesfatin-1 – A Novel Metabolic Peptide 
It has been shown that a secretory protein NEFA (Nuclear EF-hand acidic, Ca2+ 
binding) or NUCB2, which has a calcium-binding domain (EF domain) and DNA-binding 
domain, is present in the hypothalamic appetite regulating nuclei [179]. In order to find 
new satiety substances, Oh-I and colleagues [9] surveyed genes that are activated by 
troglitazone, a peroxisome proliferator activated receptor γ (PPARγ) agonist. They found 
the NEFA/NUCB2 gene upregulated both in the brain and adipocytes. In silico analysis 
predicted the proteolytic processing of NUCB2 by prohormone convertases (PC), 
resulting in an N-terminal fragment of 82 amino acids. The expression of the N-terminal 
fragment of NUCB2 in the hypothalamic PVN and cerebrospinal fluid was decreased by 
fasting in rats. As the intracerebroventricular (I.C.V) injection of this fragment in rats 
suppressed food intake, they named this processed peptide nesfatin-1 
(NEFA/nucleobindin-2 Encoded Satiety and FAT influencing proteIN-1) [9]. The 396 
amino acid precursor NUCB2 is highly conserved among rodents, humans and non-
mammals, indicative of its physiological importance [180]. In addition, the processing also 
could result in two C-terminal peptides nesfatin-2 (85-163) and nesfatin-3 (166-396), 
which have no known biological function [9]. The active site of nesfatin-1 is located in the 
mid-segment of 30 amino acids (23-53 amino acid, Figure 1.3) as the injections of C-
terminal (1-23) and N-terminal regions (54-82) had no anorectic effect in mammals [9, 
181]. The mid segment is similar to the amino acid sequence of α-MSH and agouti-related 
peptide (AgRP) and this sequence is critical for its anorexigenic activity [182]. 
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Figure 1.3. A schematic of nesfatin-1 processing from its precursor NUCB2. The 
preprohormone is cleaved by signal peptidase, yielding the prohormone. This sequence 
is then post-translationally cleaved by PC 1/3 and PC 2 resulting in 3 distinct fragments 
including nesfatin-1 (82 amino acids). Nesfatin-2 and -3 have no known biological 
functions. The mid segment of nesfatin-1 (30 amino acids) is critical for its anorexigenic 
action. 
Oh I et al., found the presence of NUCB2 in hypothalamus by 
immunohistochemical analysis in rats using NUCB2 Ab-1 antibody. They also found the 
secreted nesfatin-1 protein in rat hypothalamic extracts and cerebrospinal fluid [9]. 
NUCB2 is expressed in various hypothalamic regions like supraoptic nucleus (SON), 
paraventricular nucleus (PVN), arcuate nucleus (ARC) lateral hypothalamic area (LHA) 
and in the nucleus tractus solitarius (NTS). In spinal cord, nesfatin-1 is expressed in both 
sympathetic and parasympathetic preganglionic nerve cells and dorsal vagus nerve. Its 
presence was also confirmed by RT-qPCR in nucleus accumbens, cerebellum and 
lumber spinal cord [183]. Nesfatin-1 was co-localized with PC 1/3 and PC 2 in these 
neurons, suggesting the processing of NUCB2 by these enzymes [184]. Besides PCs, 
nesfatin-1 expressing neurons often were found to express other bioactive substances. 
In the PVN and SON of hypothalamus, nesfatin-1 is co-expressed with oxytocin and 
 22 
 
vasopressin. Nesfatin-1 positive neurons of PVN contained 24% oxytocin, 18% 
vasopressin, 13 and 18% of corticotrophin and thyroptrophin releasing hormones 
respectively (CRH and TRH). In SON, 35% of nesfatin-1 positive neurons contained 
oxytocin and 28% contained vasopressin [185]. In ARC, nesfatin-1 coexists with cocaine-
amphetamine regulated transcript (CART) and tyrosine hydroxylase, and in LH with 
CART and melanin-concentrating hormone (MCH) [186, 187]. Nesfatin-1 also co-
localizes with choline acetyl transferase in dorsal vagus nerve, and with tyrosine 
hydroxylase in NTS and with 5-hydroxytryptamine in caudal raphe [186]. It is worth noting 
that all brain-mapping studies have been performed with antibodies specific to nesfatin-1 
that also recognizes full length NUCB2. Therefore, the expression pattern cannot 
distinguish whether the distribution reflects the precursor and/or processed nesfatin-1. A 
consistent feature of NUCB2/nesfatin-1 immunostaining is its confinement to the cell-body 
cytoplasm and primary dendrites, whereas immunolabeling is completely absent in axons 
and nerve terminals. Such specific cellular localization of nesfatin-1 is at variance with 
other neuropeptides that it co-expresses, and points towards an intracellular rather than 
an extracellular mode of action for central NUCB2/nesfatin-1. Also, large set of evidence 
suggests that the neuronal effects of nesfatin-1 are mediated predominantly through the 
G-protein coupled receptors, especially GPCR12, GPCR3 and/or GPCR6 [188]. 
The presence of NUCB2/nesfatin-1 was recently characterized in non-mammalian 
vertebrates. The NUCB2 gene structure was found remarkably conserved among teleosts 
(ray-finned fishes). In zebrafish two paralogues of NUCB2 gene namely NUCB2A and 
NUCB2B exists due to teleost-specific whole genome duplication. The NUCB2 in goldfish 
and zebrafish were closely aligned and were highly similar. The nesfatin-1 region of 
goldfish NUCB2A had high percent similarity to nesfatin-1 region in zebrafish (94%), 
medaka (91%), stickleback (86%) and green pufferfish (84%). Phylogenetic analysis 
showed that the goldfish NUCB2A amino acid sequences is clustered with NUCB2A 
sequences of other teleost fishes while showing strong clustering with zebrafish NUCB2A. 
These data provided the first set of evidence for the expression and modulation of 
NUCB2/nesfatin-1 in non-mammalian models [180]. 
In peripheral tissues, nesfatin-1 is expressed in ghrelin producing X/A like cells in 
the stomach gastric oxyntic mucosa and to a smaller extent in enterochromaffin like cells 
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of gastric corpus oxyntic mucosa [14]. Subsequent studies have confirmed the presence 
of a circulating hormone [189]. Expression of NUCB2 mRNA is found to be 10 fold higher 
in gastric mucosa than in brain, suggesting stomach as the main source of circulating 
nesfatin-1 [14]. Confocal microscopy of single X/A like cell revealed that NUCB2/nesfatin-
1 immunoreactivity (IR) is localized in different pool of cytoplasmic vesicles from ghrelin. 
Nesfatin-1 has been reported to cross the blood-brain barrier via a non-saturable 
mechanism, providing the possibility that nesfatin-1 produced in stomach may act 
centrally [190]. The half-life of nesfatin-1 in circulation is 6-7 minutes [191]. Our lab, for 
the first time showed that nesfatin-1 and insulin are co-localized in the pancreatic islet β-
cells, suggesting its viable role in insulin secretion and glucose homeostasis in vitro [12]. 
Similar to X/A like cells, the sub-cellular distribution of NUCB2/nesfatin-1 and insulin are 
not identical [10]. These data along with the distinct responses of circulating 
NUCB2/nesfatin-1 to a meal compared with that of insulin or acyl ghrelin in healthy 
subjects [192] support a differential regulation and release of these hormones. Recent 
studies also have confirmed the presence of NUCB2/nesfatin-1 in intestine and colon via 
immunohistochemical staining and Western blot analysis [15, 193]. The prominent and 
consistent immunolabeling of nesfatin-1 in endocrine cells [193] and adipose tissue [9] 
strongly suggests a role as a circulating hormone involved in various homeostatic 
processes. This consensus is supported by studies in mice showing that circulating 
nesfatin-1 similar to other gut hormones influences food intake [189], can cross blood-
brain barrier bi-directionally and via a non-saturable mechanism [190]. A similar evidence 
was shown indirectly in a recent clinical study, where a significant linear relation between 
plasma NUCB2/nesfatin-1 and cerebrospinal fluid NUCB2/nesfatin-1 levels in both lean 
and to a lesser degree in fasted obese subjects [194]. Besides stomach, pancreas and 
intestine nesfatin-1 was also reported in other peripheral tissues like testis, and cardiac 
muscles [11, 195] of rodents and in goldfish [180]. All these studies collectively reiterate 
nesfatin-1 as a novel peptide expressed equally in CNS and periphery, which is involved 
in regulation of appetite and feed intake. 
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1.2.4. Nesfatin-1 Regulation of Appetite and Metabolism 
 The first biological action described for NUCB2/nesfatin-1 was reduction of dark 
phase (phase where nocturnal rats/mice ingest most of their diet) feed intake after 
injection into the third brain ventricle in rats and reduction in body weight gain and fat 
pads upon I.C.V administration [9]. Compelling evidences via functional tests showed that 
injection of nesfatin-1 into brain elicits an anorexigenic response in rodents [196-198] as 
well as in goldfish [180]. Microstructure analysis of meal patterns in mice documented 
that the anorexigenic action of nesfatin-1 is due to induction of satiation, involving both 
reduction in meal size and meal frequency when injected into the lateral brain ventricle, 
4 hours post-administration in dark phase [198]. Nesfatin-1 injected into the cisternae 
magna or the fourth ventricle also reduces dark-phase food intake within the first hour 
after injection, indicative of specific hindbrain sites of its action [199]. Since most 
hypothalamic peptides that influences food intake also affect digestive processes 
peripherally [200] a direct modulation of gastrointestinal propulsive function was proposed 
for nesfatin-1. Accordingly, it was demonstrated that injection of nesfatin-1 into lateral 
brain ventricle delayed gastric emptying in rats [200] as well as in mice [197] and affected 
gastroduodenal motility in mice [201]. These gut motility effects could contribute to the 
satiety actions. 
The mechanism of nesfatin-1 action in the brain has been established to be 
independent of leptin action in a variety of studies [9, 197, 202]. However, it involves 
several hypothalamic pathways regulating feed intake. In rats, lateral brain ventricle 
injection of nesfatin-1 caused a decrease in food intake in dark period by 87% and 45% 
at 2-3 hours and 3-5 hours after injection, respectively. This action of nesfatin-1 involved 
the activation of anorexigenic CRF receptor 2 (CRF2) signaling system, as the injection 
of corticotrophin releasing factor (CRF2) antagonist astressin2-B into lateral brain ventricle 
blocked the decrease in food intake by nesfatin-1 [199]. However, astessin2-B did not 
modify the effect of nesfatin-1 on food intake when nesfatin-1 was administered into the 
brain medulla at the level of the fourth ventricle, further supporting the notion that 
differential forebrain and hindbrain downstream signaling cascades exist for nesfatin-1. 
Also, intraperitoneal (I.P) injection of CCK induced c-fos expression in 43% of nesfatin-1 
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neurons in the PVN and 24% of nesfatin-1 neurons in NTS. This indicates that nesfatin-
1 acts centrally to reduce dark phase food intake through CRF2 receptor-dependent 
pathway after forebrain injection and its acts via CRF2-independent pathway after 
hindbrain injection. The activation of nesfatin-1 neurons in PVN by CCK suggested a 
possible role of gut-derived peptides in its satiation effect. In the PVN oxytocinergic 
neurons, nesfatin-1 stimulated oxytocin release. Oxytocin release from these neurons 
was suppressed when endogenous nesfatin-1 was neutralized immunochemically. Both 
melanocortin 3/4 antagonist SHU9119 as well as oxytocin antagonist blocked the 
forebrain nesfatin-1 induced reduction in food intake in rats [203, 204]. Whether nesfatin-
1 acts in series or parallel activates CRF2, melanocortin 3/4 and oxytocin pathways 
remains to be elucidated. In addition to the activation of anorexigenic pathways, nesfatin-
1 was also shown to suppress orexigenic pathways such as NPY signaling based on an 
in vitro study and whole cell clamp recordings from rat ARC. The study showed 
hyperpolarization of NPY neurons when nesfatin-1 was applied to the cell [205]. Besides, 
in non-mammalian vertebrates, nesfatin-1 had an appetite regulatory effect on goldfish 
[180]. NUCB2 mRNA was detected centrally in hypothalamus, olfactory bulbs, 
telencephalon, midbrain and hindbrain. A 2 to 3 fold increase in hypothalamic NUCB2 
mRNA expression was observed in fed goldfish when compared to fish deprived of food 
for 3 to 7 days. Consequently, the levels of circulating nesfatin-1 were also found to be 
lower in food-deprived goldfish compared to fed controls [180]. I.C.V injection of 25 ng/g 
synthetic goldfish nesfatin-1 reduces food intake by approximately 50%. 
Convergent sets of evidence support the physiological role of nesfatin-1 as a 
negative modulator of feed intake. First, the most abundant mRNA/protein expression of 
NUCB2/nesfatin-1 is detected in hypothalamic nuclei and brainstem areas that 
contributes to the regulation of feed intake [9]. Functional studies established that 
injection of nesfatin-1 into cerebrospinal fluid at picomolar doses induces an anorexigenic 
effect in rodents and goldfish [180, 199]. Second, other food intake suppressing signals 
such as α-MSH and CCK increases NUCB2 mRNA expression to activate 
NUCB2/nesfatin-1 immunopositive neurons in hypothalamus and brainstem. Third, 
injection of anti-NUCB2 antisense oligonucleotide or anti-nesfatin-1 antibody into third 
ventricle increases food intake in male rats [9]. However, a recent report showed that 
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knocking-down hypothalamic NUCB2 had no effect on feed intake and weight gain in 
female rats [206]. Whether the effects of nesfatin-1 are sex specific needs to be clarified. 
Also, the intracellular mechanism of nesfatin-1’s anorexigenic action remains to be 
elucidated owing to the lack of identification of its receptor. One recent reports suggests 
that the neuronal effects of nesfatin-1 are mediated predominantly through the G-protein 
coupled receptors, especially GPCR12, GPCR3 and/or GPCR6 [188]. 
A majority of studies have focused on its central effects. However, reports 
investigating its peripheral effects are limited and are less consistent. One group of 
investigators has shown that I.P injection of a large dose of nesfatin-1 in ad libitum fed 
mice reduces dark phase food intake through leptin-independent mechanisms [182]. 
Based on in vitro data that shows nesfatin-1 activating Ca2+ influx in primary cultured 
nodose (tightly grouped) ganglion neurons from mice, the above effects are likely 
mediated via the vagus nerve [207]. However, in separate studies, I.P injection of 
nesfatin-1 did not decrease the dark phase feed intake in mice as well as in rats [198, 
199]. In goldfish either no effect or an 18% decrease in food intake was observed at doses 
10 fold higher than those injected intracerebroventricularly, leading to a striking food 
intake reduction [180]. Therefore, data so far suggests that the satiety action of nesfatin-
1 is more readily inducible centrally than peripherally. This warrants further investigation 
in the context of high levels of gastric NUCB2 mRNA expression and the circulating levels 
being regulated according to nutritional status.  
A recent clinical study with healthy non-obese subjects showed negative 
correlation between BMI and fasting plasma levels of nesfatin-1 measured using nesfatin-
1 specific ELISA. However, healthy humans do not show a nutrient-related fluctuation in 
plasma nesfatin-1 levels under conditions of decreased acyl-ghrelin and increased insulin 
[11, 192]. Other studies in humans have reported a positive correlation between BMI and 
fasting plasma nesfatin-1 levels under conditions of anorexia nervosa [208] and higher 
levels in obese subjects, indicating that circulating nesfatin-1 levels are possibly regulated 
by sustained changes in adipose tissue mass. A recent report showing a lower ratio of 
CSF/plasma NUCB2/nesfatin-1 levels in obese compared to lean subjects, suggests a 
reduced uptake from circulation to brain and therefore a reduced central action from 
peripheral sources of nesfatin-1 [194]. Moreover, the reported difference in eight distinct 
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single nucleotide polymorphism in NUCB2 gene being associated with obesity in large 
cohort of male subjects provides strong evidence for the crucial role of NUCB2/nesfatin-
1 in susceptibility or protection against development of obesity [209]. Interestingly, 
NUCB2 is highly homologous to nucleobindin-1 (NUCB1), a homologous multi-domain 
calcium and DNA binding protein similar to NUCB2. 
1.2.5. Nesfatin-1 Regulation of Insulin Secretion in Mammals 
Normal insulin secretion contributes to glucose uptake and use in insulin-
responsive cells. The secreted monomer of insulin is 51 amino acids long with molecular 
weight of 5.8kDa. The insulin gene also encodes a 110 amino acid precursor for insulin 
called preproinsulin. Preproinsulin has a hydrophobic N-terminal signal peptide. This 
signal peptide interacts with the cytosolic signal recognition particles (SRP), which aids 
in the translocation of preproinsulin mRNA across the rER (rough endoplasmic reticulum) 
membrane into the lumen [210]. This process occurs via the peptide-conducting channel 
where the signal peptide at the N-terminal end of preproinsulin is cleaved by signal 
peptidase to yield proinsulin [211]. Proinsulin then undergoes folding and formation of 
three disulfide bonds. Subsequent to the maturation of the 3D confirmation, proinsulin is 
transported from ER to Golgi apparatus where it enters the secretory vesicles and is 
cleaved into insulin and C-peptide. Both the peptides are stored in these granules along 
with other endogenous peptides (e.g. amylin) until translocation and release in response 
to glucose stimulus. Insulin secretion from the β-cells of pancreatic islets is regulated by 
a variety of intracellular signals, enteroendocrine hormones as well as by hypothalamic 
centers in the brain. 
 Of many modulators of insulin secretion, nesfatin-1 was recently reported to have 
anti-hyperglycemic and insulinotropic effects besides its anorexigenic action [5, 212]. Our 
lab, for the first time showed that nesfatin-1 and insulin are co-localized in the pancreatic 
islet β-cells of rodents, suggesting its crucial role in insulin secretion and glucose 
homeostasis [12]. A four-fold increase in nesfatin-1 levels was observed, when MIN6 
(mouse insulinoma cells) were incubated at high glucose concentrations (16.7 mM). 
Nesfatin-1 stimulates glucose stimulated insulin secretion (GSIS) from rat pancreatic 
islets in a dose-dependent manner [13]. In db/db mice, nesfatin-1 had antihyperglycemic 
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effects by lowering blood glucose levels [212]. Nesfatin-1 increases glucose-stimulated 
insulin secretion (GSIS) from pancreatic β-cells by direct action involving Ca2+ influx 
through L-type calcium channels [5]. It was also shown to increase the preproinsulin 
mRNA expression in MIN6 cells. The circulating levels of nesfatin-1 are regulated by 
nutritional status as fasting decreases, and refeeding normalizes its level. Also, nesfatin-
1 in circulation increases in response to oral glucose ingestion when compared to saline 
treated groups [198]. In Goto-Kakizaki (GK) rats with T2D, the levels of NUCB2 
immunoreactivity in islet homogenate is reduced when compared to Wistar rats and 
plasma NUCB2 concentrations showed an inverse relationship with circulating glucose 
levels during glucose tolerance tests [10]. This negative association between blood 
glucose level and nesfatin-1 was also observed in human subjects with T2D [11]. 
Similarly, nesfatin-1 levels were lower in the breast milk of subjects with gestational 
diabetes [213]. These studies highlight the role of nesfatin-1 in regulating whole body 
glucose homeostasis. 
 Simultaneously, in studies involving rats with diet-induced obesity, ICV injection of 
nesfatin-1 regulated hepatic gluconeogenesis to inhibit hepatic glucose production. It was 
postulated that nesfatin-1 does this by either decreasing the synthesis of 
phosphoenolpyruvate carboxykinase enzyme, which is a rate limiting enzyme in 
gluconeogenesis in liver or by increasing the activity of insulin hormone that causes a 
decrease in hepatic glucose production [214]. In addition, peripheral insulin injection also 
increases the activation of ARC, PVN, LHA and NTS nesfatin-1 protein expression [215]. 
Nesfatin-1 administration to hyperglycemic rats reduces blood glucose levels. Therefore, 
the anti-hyperglycemic effects of nesfatin-1 results not only from its endocrine function 
increasing insulin secretion, but also from its inhibition of hepatic glucose production by 
way of regulating glycogen synthesis and gluconeogenesis. 
 An overall assessment of the available literature on nesfatin-1 shows that it plays 
a crucial role in energy metabolism via regulation of feed intake, metabolism and glucose 
homeostasis via anti-hyperglycemic and insulinotropic actions. The regulation of energy 
metabolism involves careful coordination between neurons in the hypothalamus and their 
regulation by peripheral signals including nesfatin-1. The regulation of two classes of 
neurons i.e. the orexigenic AgRP/NPY neurons and the anorexigenic POMC/CART/α-
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MSH neurons is the essence of energy metabolism. In vitro and in vivo studies have 
shown the effects of centrally arising nesfatin-1 and nesfatin-1 from adipocytes and GI 
tract on this distinct population of neurons. Nesfatin-1 activates the POMC neurons, while 
simultaneously inhibiting the AgRP/NPY to bring about a reduction in food intake by 
directly modulating energy balance.  
 
Figure 1.4. Some of the major effects of nesfatin-1 in regulating food intake and energy 
balance, by integrating its peripheral and central actions. 
1.2.6. Nucleobindin-1 – Expression and Function 
Nucleobindin-1 (NUCB1) is a 55 kDa multi-domain protein identified first in a 
culture supernatant of B lymphocyte cell line identified from mice prone to systemic lupus 
erythematosus, an autoimmune disorder. The first paper that reported this peptide 
indicated that it has a potential role in autoimmunity and apoptosis [17]. It is also called 
CALNUC owing to its Ca2+ and DNA-binding ability. The DNA binding domain of basic 
residues (172-218) lies in the N-terminus following the signal sequence. The Ca2+ domain 
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is at the core of the protein sequence consisting of two EF hand motifs with an intervening 
acidic region (residues 253-316). The Ca2+ domain is followed by a leucine zipper domain 
(residues 347-389) that has been proposed to induce its dimerization [19]. The C-terminal 
region that follows the leucine zipper region is intrinsically disordered and unstructured. 
NUCB1 sequence is strongly conserved across species from flies to humans [216] and is 
widely distributed among golgi, nucleus, endoplasmic reticulum and cytoplasm [17, 22, 
23, 217]. NUCB1 immunoreactivity has been reported in several primary cells and cell-
lines of rats, mice, monkeys and humans (HeLa cells). NUCB1 displayed partial co-
localization when co-labeled with α-Man II (a Golgi marker) and ERGIC-53 (cis-Golgi 
network marker) [18]. Immunogold labelling on ultrathin cryosections of ArT-20, normal 
rat kidney epithelial (NRK) cells and rat anterior pituitary, liver and kidney tissues 
demonstrated that NUCB1 was concentrated on the cisternae and vesicles present on 
the cis side of the golgi stack [20, 218].  
The endogenous expression profile of NUCB1 was evaluated extensively, showing 
that NUCB1 is present in pancreatic islets as well as in other endocrine tissues including 
stomach, intestine, adrenal gland, pituitary, ovary and testis [219]. Immunofluorescence 
staining performed on formalin fixed sections showed NUCB1 to be localized in the 
endocrine pancreas with no signals in the surrounding exocrine acinar cells or pancreatic 
ducts. NUCB1-IR was broadly distributed in pancreatic islets being detected along with 
glucagon, insulin, somatostatin, pancreatic polypeptide and ghrelin immunopositive cells. 
This cellular localization of NUCB1 is also suggestive of the proposed insulinotropic 
action. Subcellular localization of NUCB1 using organelle specific protein stains showed 
NUCB1 to be co-distributed with golgi apparatus protein giatin. NUCB1-IR was found all 
through the GI tract but not in all endocrine cell types. In stomach, the NUCB1 signal was 
concentrated in the fundus region of gastric glands, whereas neck and gastric pits 
displayed no immunoreactivity for NUCB1. NUCB1-IR was found in duodenum, jejunum 
and colon being primarily present in the duodenal enterocytes. Strong IR was observed 
in deep intestinal glands wherein cells immunopositive for somatostatin and ghrelin 
showed NUCB1-IR. NUCB1-IR was also observed in principal cells of parathyroid, thyroid 
follicles, adrenal medulla and zona glomerulosa of adrenal cortex, seminiferous tubules 
in testes and follicular cells of ovary. NUCB1-IR was detected in corticotropes, 
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somatotropes, thyrotropes, lactotropes and gonadotropes in the anterior pituitary. In 
addition, it has been shown that extracellular NUCB1 to be secreted into bone osteoid 
(unmineralized organic portion) possibly modulating matrix maturation via paracrine 
action [21]. These studies indicate the role of NUCB1 in multiple cellular processes. Given 
the cytoplasmic location of this protein and that it could be secreted, points towards a 
potential endocrine function for NUCB1 and/or encoded proteins. 
 NUCB1 has been reported to play an important role in the maintenance of Ca2+ 
homeostasis [22] and to interact with G proteins and cyclooxygenases [22, 23]. The C 
terminal of NUCB1 is highly acidic, giving it a low affinity and high capacity binding to 
Ca2+. Previous studies have reported that NUCB1 changes its conformation when Ca2+ 
binds to the EF hand domains with the intervening acidic domain, that represents a coiled-
coil region [220]. NUCB1 has been demonstrated with Gα subunit excluding Gαi, Gα12 and 
Gα13 [217]. NUCB1 specifically binds to α5 helix region of Gαi3 subunit and this interaction 
is dependent on Ca2+ and Mg2+ divalent cations. Studies have reported that high 
expression of NUCB1 results in redistribution of Gαi1 subunit to the plasma membrane 
and secreted granules [217]. Results from in vitro pull down assays shows that NUCB1 
interacts strongly with Gαi3 subunit only in the presence of both ions and that the 
interaction is weak with presence of either Ca2+ or Mg2+ [221]. A soluble form of NUCB1 
called sNUCB1 has also been identified that binds to Ca2+ and exists as a dimer in 
solution [221]. sNUCB1 in the unbound state (without Ca2+) interacts with inactive GDP 
bound state of Gαi1 subunit, thus inhibiting GDP release. This is reversed when sNUCB1 
is bound to Ca2+ [221]. Also, overexpression of sNUCB1 in HEK293 cell lines results in 
decreased receptor mediated Gαi1 inhibition of adenylyl cyclase, explaining the 
physiological relevance of sNUCB1 and GDI activity.  
NUCB1 was reported to be COX-2-associated (cyclooxygenase-2) protein that has 
an impact on prostanoid (cyclooxygenase metabolites of arachidonic acid including 
prostaglandins) biosynthesis. In golgi and ER of human neutrophils, NUCB1 is localized 
with COX-2. It interacts with COX-2 with high affinity resulting in an increase of 
prostaglandin E2 (PGE2) generation [23]. This was further reiterated by the study wherein 
the addition of human recombinant NUCB1 (hrNUC) to hrCOX-2 increased PGE2 
production up to 5-fold from the basal levels independent hrNUC of concentration [23]. 
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This modulation of COX-2 by NUCB1 is important because COX-2 activity is involved in 
the development of cancer by promoting cell division [222]. NUCB1 acts as a negative 
regulator of unfolded protein response (UPR) that is involved in inhibiting the site 1 
protease (S1P) mediated cleavage of activating transcription factor 6 (ATF6) in golgi 
apparatus during ER stress [223]. Results obtained so far reiterate the importance of 
NUCB1 as an intracellular regulatory protein. 
On comparing NUCB1 and NUCB2, both proteins are found encoded by two 
unlinked genes. However human NUCB1 and NUCB2 exhibit 62% amino acid sequence 
identity. Compared to NUCB1, NUCB2 is 40 residues shorter and is approximately a 
50kDa protein in humans and rodents [224]. While NUCB2 encodes nesfastin-1, no 
information exists regarding NUCB1 encoded peptides so far. Similar to the primary 
structure of NUCB2, NUCB1 also has 24 amino acid signal peptide sequence (Figure 
1.5, in italics) followed by a signal peptidase cleavage site between position 26 and 27. 
This is followed by a region that has high similarity to nesfatin-1 region of NUCB2 (shown 
in bold) containing a mid-segment of 30 amino acids (underlined) and a prohormone 
convertase cleavage site. In comparison to NUCB2 the proposed mid segment of 30 
amino acids in NUCB1 has less similarity to active sites of AgRP and α-MSH. 
E.g. Human NUCB1 precursor (NP_006175.2) 
 
 1 mppsgprgtl lllpllllll lravlavple rgapnkeetp atespdtgly yhrylqevid 
       61 vletdghfre klqaanaedi ksgklsreld fvshhvrtkl delkrqevsr lrmllkakmd 
      121 aeqdpnvqvd hlnllkqfeh ldpqnqhtfe ardlelliqt atrdlaqyda ahheefkrye 
      181 mlkeherrry leslgeeqrk eaerkleeqq rrhrehpkvn vpgsqaqlke vweeldgldp 
      241 nrfnpktffi lhdinsdgvl deqelealft kelekvydpk needdmreme eerlrmrehv 
      301 mknvdtnqdr lvtleeflas tqrkefgdtg egwetvemhp ayteeelrrf eeelaareae 
      361 lnakaqrlsq etealgrsqg rleaqkrelq qavlhmeqrk qqqqqqqghk apaahpegql 
      421 kfhpdtddvp vpapagdqke vdtsekklle rlpevevpqh l 
 
Figure 1.5. The amino acid sequence of human NUCB1 precursor. 
1.3. RATIONALE 
Recent studies using immunohistochemical staining in ad libitum fed rats showed 
no nesfatin-1 immunopositive cells in the intestine [14]. However, this view is challenged 
by our recent findings wherein we detected both NUCB2 mRNA and protein expression 
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in the intestine of ad libitum fed C57BL/6J mice [15]. Additional studies that showed 
NUCB2 mRNA expression and nesfatin-1 immunolocalization in the small intestine of rats 
are also supportive of this [193, 219]. Does nesfatin-1 has a direct role in modulating the 
secretion of enteric hormones that regulate insulin secretion and energy homeostasis? 
The cytoplasmic presence of NUCB1, and that it is a secreted protein (found in bones, 
cerebrospinal fluid and rat hypothalamic extracts) suggests a possible endocrine function 
for NUCB1 and a potential NUCB1-encoded peptide called nesfatin-1-like peptide (NLP). 
Interestingly, the nesfatin-1 region of NUCB1 and nesfatin-1 region in NUCB2 are highly 
conserved in humans, with 68% amino acid sequence identity. In addition, both NUCB1 
and NUCB2 sequences retain the prohormone convertase cleavage sites [225]. 
Therefore, the possibility of NUCB1 and/or NLP eliciting biological actions similar to that 
of NUCB2/nesfatin-1 could not be ruled out. Does NUCB1 encode a bioactive nesfatin-1-
like peptide (NLP)? Is NLP insulinotropic? 
1.4. HYPOTHESES  
Based on the information discussed above, the central hypothesis of this thesis 
research is that (1) nesfatin-1 has a direct role in modulating enteric hormone secretion, 
and (2) a nesfatin-1 like peptide is encoded in NUCB1 and this peptide has insulinotropic 
action. 
1.5. SPECIFIC OBJECTIVES  
The specific aims of this thesis research are to: 
 
(1) determine the presence and co-localization of endogenous NUCB2/nesfatin-1 with 
major enteric hormones in mouse intestine and in vitro in a mouse intestinal cell line (STC-
1). 
 
(2) test whether nesfatin-1 regulates enteric hormones in vitro in STC-1 cells, and in vivo 
in male mice. 
 
(3) identify the nature of NUCB1 encoded NLP in silico, and NUCB1 expression in various 
nutrient states. 
 
(4) elucidate the in vitro effects of NLP on insulin expression/secretion, and in vivo effects 
on dark and light phase food intake in male mice. 
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TRANSITION 
 
The following chapter focuses on objectives 1-2, to determine the nesfatin-1 regulation of 
enteric hormone secretion. As discussed earlier, we observed endogenous 
NUCB2/Nesfatin-1 mRNA in the intestine of C57BL/6J mice by RT-qPCR and gel 
electrophoresis. Subsequently, we also observed NUCB2 protein expression in intestine 
by Western blotting of total protein samples from intestinal sections of ad libitum fed male 
C57BL/6J mice. This chapter will elaborate the studies carried out, major techniques used 
for answering my specific research question mentioned above and the results obtained. 
This is followed by a discussion and conclusion of my findings pertaining to the research 
question. 
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CHAPTER 2 
NESFATIN-1 REGULATION OF ENTERIC HORMONE SECRETION 
2.1. INTRODUCTION 
 The GI tract is the primary center for nutrient absorption and assimilation. Besides, 
GI tract is also a major endocrine organ secreting a variety of enteroendocrine hormones. 
The vagus nerve is a main communication route between the central nervous system 
(CNS) and the enteric nervous system (ENS) that is responsible for proper GI functions 
including gastric motility, enzyme secretion and nutrient sensing [226]. The enteric 
hormones are secreted from specialized enteroendocrine cells in response to chemical 
and mechanical stimuli in the gut, resulting from food intake. Upon secretion they bind to 
their receptors in vagal afferent neurons communicating the peripheral nutritional status 
to CNS [227]. As discussed elaborately in chapter 1, GLP-1, GIP, CCK and PYY are major 
enteric hormones secreted from the GI tract. 
Nesfatin-1 is a recent addition to the list of anorexigenic peptides capable of 
inducing satiety [9]. NEFA/nucleobindin-2 Encoded Satiety and FAT influencing proteIN-
1, abbreviated as nesfatin-1 is an anorectic peptide cleaved from the N-terminal of 
nucelobindin-2 (NUCB2). The prohormone of NUCB2 is then post-translationally cleaved 
into three distinct fragments named nesfatin-1 (1-82 amino acids), nesfatin-2 (85-163 
amino acids) and nesfatin-3 (166-396 amino acids). The 82 amino acid nesfatin-1 has a 
23 amino acid N-terminal segment, 29 amino acid C-terminal segment and a 30 amino 
acid mid segment (Figure 1.3). Of the three segments, the mid segment is the bioactive 
core having anorectic activity [9]. Nesfatin-1 has been reported to be expressed in 
peripheral tissues ranging from stomach [14], pancreas [12], gut [193] and cardiac 
muscles [195]. I.C.V injection of nesfatin-1 reduces dark phase food intake and body 
weight gain in rats [9]. Opposing evidences exist regarding the expression of 
NUCB2/nesfatin-1 in the intestine. Although nesfatin-1 is expressed predominantly in 
gastric oxyntic mucosa in X/A like cells, the original study that reported this in ad libitum 
fed rats showed no nesfatin-1 immunopositive cells in intestine [14]. This view is 
challenged by our recent findings where both NUCB2 mRNA and protein expression was 
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confirmed in the intestine of ad libitum fed C57BL/6J mice [15]. This is supportive of 
previous observations by Zhang et al., [193] that showed NUCB2/nesfatin-1 
immunoreactivity and protein expression in various sections of intestine. Nesfatin-1, 
besides being a modulator of food intake, also stimulates GSIS from rat and mouse 
pancreatic islets in a dose-dependent manner [5]. Also, the role of intestinal hormones on 
insulin secretion and food intake has been studied extensively [89, 117, 141, 142, 160, 
176, 228].  
Taken together, the main hypothesis behind the research in this chapter is that 
NUCB2/nesfatin-1 is expressed in the intestinal enteroendocrine cells and that it regulates 
intestinal hormone secretion. This study determined that the enteroendocrine cell line 
STC-1 expresses NUCB2 mRNA and also show NUCB2/nesfatin-1 immunoreactivity 
when incubated with a highly specific NUCB2 antibody. Further, immunohistochemical 
analysis of intestinal sections from ad libitum fed mice showed NUCB2 immunoreactivity 
to be co-localized with GLP-1, GIP, CCK and PYY immunoreactive cells. Subsequently, 
treatment of STC-1 cells dose-dependently with nesfatin-1, upregulated GLP-1, GIP and 
CCK, while downregulating PYY expression and secretion. Osmotic mini-pump infusion 
of 100 µg/kg body weight nesfatin-1 into C57BL/6J mice showed no changes in glucose 
handling between controls and treatments. Whether or not nesfatin-1 infusion causes an 
increase in circulating levels of the respective hormones remains to be elucidated via 
immunoassays. 
2.2. MATERIALS AND METHODS 
2.2.1. Cell Culture 
 In this study, a mouse enteroendocrine cell line, STC-1 (Cells derived from tumors 
in transgenic mice carrying transgenes consisting of rat insulin promoter 2 (RIP2) linked 
to polyoma small T antigen [PyST], hence STC) was used. Studying the gene expression 
of gut peptides has a major limitation in that their distribution is diffuse in vivo. Hence 
primary cell isolation and culture are tedious. Ideally, therefore the studies on intestinal 
peptides are being undertaken in immortalized cells that express these peptides. Cell 
lines are regularly used by several laboratories to investigate basic questions related to 
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organization and function of intestinal cells. However, intestinal enteroendocrine tumors 
are very rare and consequently are not a ready source of permanent cell lines that secrete 
all the major gut peptides [229]. The STC-1 cell line was derived from intestinal endocrine 
tumors that developed in mice carrying transgenes containing the rat insulin promoter 
linked to the potent viral oncogene SV40 T antigen and to the polyoma virus small T 
antigen [230]. 
 STC-1 cells were previously used to study the release of CCK, secretin and GLP-
1 and it was then concluded that this cell line can serve as a model system to investigate 
the secretory mechanisms for these peptides [231-233]. In addition, in the presence of 
glucose, a concentration-dependent increase in GIP gene expression was observed in 
STC-1 cells, suggesting that these glucose responsive cells express GIP in a regulated 
fashion similar to those observed in rats [228, 234]. CCK secreted from STC-1 cells was 
shown to have the same HPLC retention time as naturally occurring peptide [232]. The 
HPLC retention time for the immunoreactive GIP secreted by these cell was also shown 
to be the same as GIP derived from intestine [234]. In addition, STC-1 cells were shown 
to secrete PYY [235]. Therefore, STC-1 cells are ideal models for studying the synthesis 
and/or secretion of GLP-1, GIP, CCK and PYY.  
 STC-1 cells used here were a generous gift from Dr. Timothy Kieffer (University of 
British Columbia, Vancouver, Canada). The cells were cultured in Dulbecco’s Modified 
Eagles Medium (DMEM, Invitrogen, Catalog #11995-040) supplemented with 10% fetal 
bovine serum (FBS, Invitrogen, Catalog #12484), penicillin (100 U/mL) and streptomycin 
(100 µg/mL) (Invitrogen, Catalog #15140-122). Cells were incubated at 37°C and 5% CO2 
culture conditions in a humidified incubator to promote growth. Cell culture media was 
changes every 48 hours after washing twice with Dulbecco’s Phosphate-Buffered Saline 
(DPBS, Life Technologies, Catalog #14190-250). The cells were sub-cultured once they 
reached 85-90% confluency using 0.25% trypsin-EDTA (Life Technologies, Catalog 
#25200-056). 
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2.2.2. Animals 
Age matched (5 weeks old, average body weight: 20 grams) male C57BL/6J mice 
(Charles River Laboratories, Quebec, Canada) were housed individually in a 12 hours 
light: 12 hours dark cycle (lights off at 7 PM and on at 7 AM), temperature and humidity 
controlled vivarium. Mice had ad libitum access to standard mouse chow and water. Male 
mice were preferred owing to the sexual dimorphisms observed in endogenous NUCB2 
expression and biological functions (previous lab observations) and also to maintain 
consistency. All protocols strictly adhered to the guidelines of the Canadian Council for 
Animal Care, and were approved by the University of Saskatchewan Animal Research 
Ethics Board (Protocol # 2012-0033). 
2.2.3. Detection of Endogenous NUCB2/Nesfatin-1 in Mice Intestinal Cell Line and 
in Mice Intestine 
2.2.3.1. Immunocytochemistry and Immunohistochemistry 
 STC-1 cells were cultured on LabTek™ chamber slides to look at the indirect 
immunofluorescence. The cells were fixed in 4% paraformaldehyde for 15 minutes at 4°C 
and then washed with Dulbecco’s Phosphate Buffered Saline (DPBS, Life Technologies, 
Catalog #14190-250). After fixation, the primary antibody was added with dilution ratio 
1:200 using DAKO antibody diluent (DAKO, Catalog# S0809) in room temperature. The 
primary antibody used was rabbit anti-NUCB2 (Custom antibody, Pacific Immunology, 
Catalog# 1312-PAC-01). The primary antibody pre-absorbed in 10 µg of nesfatin-1 (200 
µg stock, >95% purity) overnight was used for pre-absorption controls to confirm the 
specificity of antibody. After six hours, the slides were rewashed with DPBS. Following 
this secondary antibody was added with dilution ratio of 1:200. Goat anti-rabbit Texas-
Red IgG (Vector Laboratories, Catalog# TI-1000) diluted with DAKO antibody diluent was 
used as secondary antibody. The slides were maintained at 37°C in a humidified 
incubator for 1 hour. The chambers were then peeled off and were allowed to dry in room 
temperature. After drying, slides were mounted with Vectashield mounting medium 
containing 4’, 6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, Catalog# H-
1200). 
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For confirming the presence of NUCB2/nesfatin-1 immunoreactivity in intestine 
and to assess its co-localization with intestinal hormones, ad libitum fed 3 months old 
male C57BL/6J mice were used. Animals were euthanized using cervical dislocation. 
Briefly both large and small intestines were collected for immunohistochemistry. The 
tissues collected were fixed in 4% paraformaldehyde for 24 hours at 4°C and were 
processed and sectioned at the center for modeling human disease (CMHD, Toronto, 
Canada). Paraffin sections of 4 µm thickness were prepared for immunostaining. These 
sections were deparaffinized with xylene (incubated twice in 100% xylene; 5 minutes at 
25°C) and rehydrated in graded ethanol series (incubated twice in 100% ethanol, once in 
each 95% ethanol, 70% and 50% ethanol, 2 minutes each at 25°C). The sections were 
then incubated with 3% hydrogen peroxide in distilled water to block endogenous 
peroxidase activity (30 minutes at room temperature). The sections were then blocked 
with serum-free protein block reagent (DAKO, Catalog# S0809) for 10 minutes before 
being incubated with primary antibodies. The primary antibodies were diluted using DAKO 
antibody diluent at different dilution ratios. The primary antibodies used are rabbit anti-
NUCB2 (Custom antibody, Pacific Immunology, Catalog# 1312-PAC-01, 1:500 dilution) 
and mouse monoclonal anti-GLP-1 (Abcam, Catalog# ab26278, 1:500 dilution) for GLP-
1 sections, Mouse polyclonal NUCB2/nesfatin-1 (ENZO Life Sciences, Catalog# ALX-
804-854-C100, 1:100 dilution) and  rabbit polyclonal anti-GIP (Abcam, Catalog# ab22624, 
1:500 dilution) for GIP sections, Goat anti-nesfatin-1 (SantaCruz, Catalog# SC65160, 
1:500 dilution) and Rabbit anti-PYY(3-36) (Phoenix pharmaceuticals, Catalog# H-59-04, 
1:200 dilution) for PYY sections, Goat anti-nesfatin-1 and rabbit anti-CCK (Abcam, 
Catalog# ab43842, 1:500 dilution) for CCK sections. After 24 hours all slides were 
washed three times with 1X PBS and incubated with secondary antibodies. The 
secondary antibodies were diluted using DAKO antibody diluent at different dilution ratios. 
The secondary antibodies used are goat polyclonal anti-mouse FITC (Abcam, Catalog# 
A-11034, 1:500 dilution) for GLP-1, goat polyclonal anti-rabbit Alexa Flour-488 
(Invitrogen, Catalog# A11037, 1:500 dilution) for GIP, goat polyclonal anti-mouse Alexa 
Flour-594 (Abcam, Catalog# ab150108, 1:500 dilution) for NUCB2/nesfatin-1 and goat 
anti-rabbit Texas-Red IgG (Vector Laboratories, Catalog# TI-1000, 1:100 dilution) for 
nesfatin-1, PYY and CCK. The slides were then washed three times with 1X PBS and 
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seven times with distilled water. Finally, the slides were mounted with Vectashield 
medium that contains the nuclear dye DAPI.  
2.2.3.2. Fluorescence Microscopy 
Once the cells and tissues were fixed and stained for NUCB2/nesfatin-1 and GLP-
1, PYY, CCK (tissues alone), the slides were viewed under a Nikon Eclipse-Ti inverted 
fluorescence microscope (Nikon, Canada) to detect indirect immunofluorescence. The 
slides were viewed in 40X magnification with blue, green and red filters specific for the 
stains used. DAPI stains the nuclei of the cells, and this was imaged under the presence 
of blue filter. Green and red filters were used for imaging cells and tissues stained with 
Texas Red and FITC green respectively. The images were captured using a Nikon DS-
Qi1 MC camera. Images were analyzed using NiS-Elements basic research software on 
a Lenovo ThinkPad workstation. 
2.2.4. Qualitative Analysis – Expression of NUCB2 mRNA in STC-1 Cells 
NUCB2 mRNA was detected in STC-1 cells using RT-qPCR followed by gel 
electrophoresis of the PCR product. The following sections will describe the procedure 
and materials used for carrying out these techniques. 
2.2.4.1. Total RNA Extraction 
 STC-1 cells were grown on 6 cm plates as described in section 2.2.1. Upon 
confluence, TRIzol® Reagent (Life Technologies, Catalog# 15596-026) was added to the 
plate kept over an ice bath. The reagent and lysed cells were collected in 1.5 mL tubes 
for total RNA extraction. Approximately 200 µL of chloroform was added to the tube 
followed by centrifugation at 13,000 rpm for 15 minutes. The supernatant containing the 
RNA was separated from DNA and protein layers. Isopropanol was added in order to 
precipitate RNA in solution. 70% ethanol was added to remove any phenol impurities from 
the pellet. Purified RNA was isolated using RNAse free water (35 µL). The quality and 
quantity of RNA extracted was determined using Nanodrop™ 2000C (Thermo Scientific, 
Canada). Total RNA was quantified by measuring the optical density (OD) and absorption 
ratio (A260 nm/A280 nm) of diluted RNA. Pure RNA will have a ratio of approximately 
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2.0. The ratio of the samples used for my study ranged from 1.9 - 2.0. All RNA samples 
used for cDNA synthesis and RT-qPCR had high quality. Isolated RNA was stored at -
80° C until further analysis. 
2.2.4.2. cDNA Synthesis 
Synthesis of cDNA was conducted using iScript™ Reverse Transcription Supermix 
(Bio-Rad, Catalog# 170-8840) for RT-qPCR as directed by the manufacturer. The 
reaction set up for cDNA synthesis is described in Table 2.1, and the conditions used in 
Thermo cycler (Bio-Rad, Canada) is described in Table 2.2. cDNA samples were stored 
at -20°C until required for PCR analysis. 
Table 2.1. Reaction setup for cDNA synthesis using iScript DNA synthesis kit (as 
provided by manufacturer; Bio-Rad). 
Components Volume Used 
Nuclease Free Water 14 µL – 1/Conc of RNA 
5X iScript reaction mixture 4 µL 
RNA Template 1/Conc 
iScript Reverse Transcriptase 1 µL 
Total Volume 20 µL 
 
Table 2.2. Reaction protocol optimized for cDNA synthesis using thermo cycler. 
 Step 1 Step 2 Step 3 Step 4 
Temperature 25°C 42°C 85°C 4°C 
Time 5 minutes 30 minutes 5 minutes Infinite Hold 
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2.2.4.3. Reverse-Transcription Polymerase Chain Reaction 
 The cDNA synthesized was used as template to determine the qualitative 
expression of NUCB2 in STC-1 cells. The primer sequences were obtained from National 
Center for Biotechnology Information Gene Bank (NCBI) and the primers were 
synthesized using Primer-BLAST™, primer designing tool from NCBI 
(www.ncbi.nlm.nih.gov/tools/primer-blast/). The GenBank accession number is given 
under each gene. The forward and reverse primers are provided in Table 2.3. 
Table 2.3. Primer Pairs for mouse NUCB2 and β-Actin with Respective Annealing 
Temperatures 
Gene Forward (5’ – 3’) Reverse (3’ – 5’) Amplicon 
Size (bp) 
Annealing 
Temperature 
Mouse NUCB2 
(NM_001130479.2) 
 
ccagtggaaaatgcaa
ggat  
gctcatccagtctcgt
cctc 
 
202 61°C 
Mouse β-Actin 
(NM_007393.3) 
 
ccactgccgcatcctctt
cc 
 
ctcgttgccaatagtg
atgac 
 
77 60°C 
 
 Primers were validated and optimized for high primer efficiency and annealing 
temperatures. The primers were then used for conducting qualitative PCR. The PCR 
samples were run on a thermo cycler (Bio-Rad, Canada) for 35 cycles. The samples were 
stored at -20°C until gel electrophoresis. The components of the mastermix are provided 
in Table 2.4. The components for the qualitative PCR are provided in Table 2.5. The 
reaction protocol used is described in Table 2.6. 
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Table 2.4. Components of Reaction Mastermix for qualitative PCR 
Components Volume Required 
10X PCR buffer reaction mixture 100μL 
25nM MgCl2 60μL 
dATP 5μL 
dTTP 5μL 
dCTP 5μL 
dGTP 5μL 
Sterile water 820μL 
 
Table 2.5. Reaction Components for qualitative PCR 
Components Volume Required 
Mastermix 20μL 
Forward Primer 1μL 
Reverse Primer 1μL 
cDNA template 1μL 
Taq Polymerase 0.5μL 
Total Volume 23.5μL 
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Table 2.6. Optimized PCR conditions with respective annealing temperatures for 
NUCB2 and β-Actin. (Step 1: Initial Activation; Step 2: Denaturation; Step 3: 
Annealing; Step 4: Elongation; Step 5: Infinite Hold) 
 Step 1 Step 2 Step 3 Step 4 Step 5 
Temperature 95°C 95°C Annealing 
Temp 
73°C 4°C 
Time 5 minutes 30 seconds 30 seconds 30 seconds Infinite Hold 
 
2.2.4.4. Gel Electrophoresis 
 Following PCR, the samples were run on 1.5% agarose gel. 1.5 gram of agarose 
(Invitrogen, Catalog# 16500-500) was mixed with 1X TAE buffer (Fischer Scientific, 
Catalog# BP1332-1, 50 X). Approximately 5 μL of ethidium bromide (Invitrogen, Catalog# 
15585-011) was added and the mixture was allowed to set in the electrophoresis tray. 
Prior to setting, a comb was placed. Once set, the comb was taken out and the 
electrophoresis chamber was filled with 1 X TAE buffer. This was followed by the addition 
of 3 μL of 10 X gel loading buffer (Invitrogen, Catalog# 10816-015) to the PCR samples 
and approximately 20 μL of sample were loaded into each well. One Kb plus DNA ladder 
(5 μL) (Invitrogen, Catalog# 10787-018) was loaded alongside the samples to detect the 
amplicon gene. The gel was run from negative to positive, as DNA is negatively charged, 
for one and half hour at 120 V. The image was obtained using GelDoc™ EZ system (Bio-
Rad, Canada) and the expression of genes of interest was qualitatively analyzed. 
2.2.5. Dose Dependent Effects of Nesfatin-1 on the Expression of Proglucagon, 
GIP, CCK and PYY mRNAs in STC-1 Cells 
 This study was conducted to determine proglucagon (GLP-1), GIP, CCK and PYY 
mRNA expression in STC-1 cells after treatment with nesfatin-1. Cells were cultured as 
described in section 2.2.1. Twenty four hours prior to study, cells were seeded into 24-
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well plates at 2 X 105 cells/well in 1 mL DMEM (80% confluence). On the day of study, 
wells were washed twice with 1 X DPBS (1 mL/well). The cells were then incubated for 1 
hour with DMEM containing 10, 1, 0.1, 0.01 and 0.001 nM (n = 8 wells/treatment) rat full 
length nesfatin-1 (Abgent Technologies, USA, >95% purity). Controls were incubated with 
culture media without nesfatin-1 for the same period of time. The studies were repeated 
twice and data from these independent studies were pooled. Total RNA extraction and 
relative gene expression was determined as described below. 
2.2.5.1. Total RNA Extraction 
 Cells were collected from each study to assess the relative mRNA expression of 
enteric hormones. Extraction of RNA was carried out using the TRIzol reagent procedure 
as described in section 2.2.4.1. The purity of RNA was determined using Nanodrop 
2000C. The RNA is stored in -80°C until further required. 
2.2.5.2 cDNA Synthesis 
 cDNA was synthesized using iScript cDNA synthesis kit as described in section 
2.2.4.2. The samples were stored at -20°C until used as a template for quantitative PCR.  
2.2.5.3. Real Time Quantitative PCR 
The relative mRNA expression of enteric hormones (GLP-1, GIP, CCK and PYY) 
was conducted using iQ™ SYBR® green supermix (Bio-Rad, Catalog# 170-8880) for 35 
cycles. All reactions were performed with final volume of 20μL as per Table 2.7. The 
reaction protocol was set up with CFX connect real time PCR detection system (Bio-Rad, 
Canada) as per Table 2.8. Forward and reverse primers for proglucagon, GIP, CCK and 
PYY were synthesized as described in section 2.2.4.3 and are provided in Table 2.9 (for 
β-Actin primers refer Table 2.3). 
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Table 2.7. Components of PCR Reaction Set Up. 
Components Volume per reaction 
iQ™ SYBR® Green Supermix 10μL 
Forward Primer 0.5μL 
Reverse Primer 0.5μL 
cDNA template 1μL 
Sterile Water 8μL 
Total Volume 20μL 
 
Table 2.8. PCR Reaction Set Up in CFX Connect.  
 Step 1 Step 2 Step 3 Step 4 Step 5 
Temperature 95°C 95°C Annealing 
Temp 
72°C 4°C 
Time 2 minutes 10 seconds 30 seconds 30 seconds Infinite Hold 
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Table 2.9. Primer Pairs for preproglucagon, GIP, CCK and PYY with Respective 
Annealing Temperatures 
Gene Forward (5’ – 3’) Reverse (3’ – 5’) Amplicon 
Size (bp) 
Annealing 
Temperature 
Mouse 
Preproglucagon 
(AF276754.1) 
 
aatcttgccaccagggactt agtgactggcacga
gatgtt 
112 56.3°C 
Mouse GIP 
(NM_008119.2) 
 
acaaagaggcacaggaga
gc 
agccaagcaagcta
aggtca 
180 60°C 
Mouse CCK 
(NM_00128450
8) 
tttcctgcccgcatttgaac aatccatccagccc
atgtagtc 
153 60°C 
 
Mouse PYY 
(NM_145435.1) 
 
ttcaggccagaaggtttgga 
 
acaccgagatatga
agtgccc 
 
122 
 
59°C 
 
 A melting curve analysis was carried out at 65°C to 95°C, which is helpful in order 
to check for any dimer formation or artifacts. CT was obtained for both reference gene 
and gene of interest. Reference genes/housekeeping genes are important in order to help 
normalize the RT-qPCR data. It is important that housekeeping genes be validated 
separately for each gene of interest and for each test group and control group. A number 
of housekeeping genes are available, including β-Actin, GAPDH and Elongation Factor 
(EF). RT-qPCR data is generally analyzed using relative quantification method rather than 
the absolute quantification. In absolute quantification, the target gene is compared to a 
standard curve, whereas in relative quantification analysis, the target gene is compared 
to a reference/housekeeping (HK) genes. The CT values for both gene of interest and HK 
genes is determined for control group and the experimental group. The data is normalized 
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to HK genes (ΔCT = CT (exp) – CT(control)). The reference gene used for this research was β-
Actin. Relative mRNA expression of enteric hormones were normalized with β-Actin from 
the same samples according to Livak method [236]. 
2.2.6. Dose Dependent Effect of Nesfatin-1 on GLP-1, GIP, CCK and PYY Secretion 
 This study was conducted to determine the changes in GLP-1, GIP, CCK and PYY 
secretion from STC-1 cells into the media, after treatment with nesfatin-1. Cells were 
cultured as described in section 2.2.1. Twenty four hours prior to study, cells were seeded 
into 24-well plates at 2 X 105 cells/well in 1mL DMEM (80% confluence). On the day of 
study, wells were washed twice with 1X DPBS (1mL/well). The cells were then incubated 
with DMEM containing 10, 1, 0.1, 0.01 and 0.001 nM (n = 8 wells/treatment) rat full length 
nesfatin-1 (Abgent Technologies, USA, >95% purity). Controls were incubated with 
culture media only (without nesfatin-1) for the same period of time. After 1 hour, media 
were collected. In order to prevent cell debris, samples were centrifuged at 13,000 rpm 
for 10 minutes at 4°C and top 500 μL was stored at -20°C until measured. The studies 
were repeated twice and data from these independent studies were pooled. The relative 
secretion levels of enteric hormones into media were measured using immunoassays as 
described below. 
2.2.6.1. Immunoassays (ELISA and RIA) 
 GLP-1, GIP and CCK secretion levels into the media were measured using the 
multispecies GLP-1 total ELISA kit (Millipore Inc., Catalog# EZGLP1T-36K), Rat/mouse 
GIP (total) ELISA kit (Millipore Inc., Catalog# EZRMGIP-55K) and rat/mouse CCK ELISA 
kit (Abnova, Catalog# KA1862) respectively. PYY in media was measured using 
rat/mouse PYY radioimmunoassay kit (Millipore Inc., Catalog# RMPYY-68HK). All 
procedures were carried out according to the manufacturer’s instructions. The limit of 
assay sensitivity was 1.5 pM, 8.2 pg/mL, 17.74 pg/mL and 15.6 pg/mL for GLP-1, GIP, 
CCK and PYY respectively. The detectable range was from 4.1 – 1000 pM, 8.2 – 2000 
pg/mL, 0.1 – 1000 pg/mL and 5 – 500 pg/mL for GLP-1, GIP, CCK and PYY respectively. 
The plates were read using SoftMAX® 190 microplate reader equipped to read 
absorbance at 450nm (Molecular Devices, USA). The amount of immunoreactive material 
 49 
 
was determined using non-linear regression curve-fit, which was used to quantify and 
compare the concentration of enteric hormone secretion in media samples. 
2.2.7. In Vivo Effects of Nesfatin-1 on Enteric Hormone Secretion in Male C57BL/6J 
Mice 
 This study was conducted to determine the changes in GLP-1, GIP, CCK and PYY 
circulation levels in the blood plasma in response to subcutaneous infusion of nesfatin-1 
using an osmotic pump. It was designed in such a way that the effect of nesfatin-1 on 
intestinal hormone release post-glucose oral ingestion can be compared with saline 
controls. Age matched (5 weeks old, average body weight: 20 grams) C57BL6J male 
mice (The Jackson Laboratory, USA) were housed as described in section 2.2.2. Mice 
were divided into two groups either infused with nesfatin-1 (n = 6) or infused with saline 
(n = 6). Mice had ad libitum access to standard mouse chow and water throughout the 
experiment. On the day of experiment, osmotic pumps (ALZET®, Catalog# 2001D) were 
filled either with saline or 100 μg/Kg body weight of nesfatin-1 dissolved in saline, as per 
the manufacturer’s instructions. The pumps were then primed over 10 cm plates 
containing 0.9% saline in an incubator at 37°C for 2 hours. This was followed by 
subcutaneous implantation of pumps into animals. The pumps were capable of delivering 
consistently 8 μL/hour of either saline or nesfatin-1 for 24 hours. During implantation, 
animals were anesthetized using isoflurane (4-5% + 0.8-1 L/min). Upon induction of 
anesthesia, the effect was maintained by isoflurane (1-3% + 0.8-1 L/min). Briefly incisions 
were made on the dorsal side of the animal’s skin between the scapulae. Using a 
hemostat, a small pouch was formed by spreading the subcutaneous connective tissues 
apart. The pumps were then inserted into the pocket with the flow moderator of the pump 
pointing away from incision. The incisions were then closed with wound clips. Animals 
were checked for normal activity and behavior upon recovery from anesthesia. 
Blood glucose levels were measured from the tail vein using glucometers 
(OneTouch™ UltraMini®) six and fifteen hours post-implantation. The animals were then 
given an oral load of 1 g/kg body weight D-glucose (Sigma-Aldrich, Catalog# G8270) 
using Popper™ animal feeding needles (Popper and Sons Inc., Catalog# 01-290-10A). 
The blood glucose levels were measured 15 minutes post oral load of D-glucose. The 
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animals were then euthanized by decapitation followed by collection of blood, pancreas, 
whole stomach, liver, large intestine and small intestine from each mice. To maintain 
consistency, the timing and duration of experiment, and sample collection were kept 
constant for all animals. 
 
 
 
Figure 2.1. A schematic of the animal studies to test the in vivo effects of nesfatin-1 on 
enteric hormone secretions. 
2.2.7.1. Immunoassays (ELISA and RIA) 
 Blood samples collected were allowed to clot on ice, and serum was separated by 
centrifugation (7000 rpm for 9 minutes at 4°C) and stored at -20° C until assays are 
conducted. GLP-1, GIP, CCK and PYY levels in circulation are yet to be measured using 
ELISA and RIA as described in section 2.2.4.1 owing to the low volumes of blood plasma 
samples obtained. 
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2.2.8. Statistical Analysis 
 Analysis of the quantified RT-qPCR and immunoassays data were conducted 
using One-way ANOVA followed by Tukey’s multiple comparison test. IBM SPSS™ 
version 21 (IBM., USA) as used for statistical analysis and GraphPad Prism version 5 
(GraphPad Inc., USA) was used for generation of graphs. Significance was assigned 
when p<0.05. All data are expressed as mean ± standard error of mean (SEM).  
2.3. RESULTS 
2.3.1. NUCB2 mRNA Expression in STC-1 Cells 
 A band of approximately 200 bp of NUCB2 mRNA was detected (Figure 2.2) in 
STC-1 cells. The no template negative control was also incorporated in the gel. 
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Figure 2.2. Gel electrophoresis image showing the presence of NUCB2 mRNA in STC-1 
cells. The amplicon size of the band was approximately 200 base pairs. The presence of 
a band provides evidence that NUCB2 mRNA is expressed in STC-1 cells and it is 
indicative that enteroendocrine cells could be a source of NUCB2/nesfatin-1 in vivo. 
2.3.2. Nesfatin-1 Immunoreactivity in the Cytoplasm of STC-1 Cells 
 Fluorescence microscopy imaging at a magnification of 40X, showed the existence 
of NUCB2/nesfatin-1 immunopositive cells. The figure below shows images of the cells 
cultured, fixed and stained in chamber slides. Nuclei were stained with DAPI and the 
immunopositive cells are stained red. NUCB2/nesfatin-1 immunoreactivity was observed 
in the cytoplasm of STC-1 cells (Figure 2.3 – (A – C)). The preabsorption control and no 
primary antibody control showed no presence of NUCB2/nesfatin-1 immunoreactivity 
(Figure 2.3 – (D – E)). 
 
Figure 2.3. Characterization of NUCB2/nesfatin-1 immunoreactivity in STC-1 cells. A 
shows staining of nucleus by DAPI. Immunocytochemical staining of STC-1 cells for 
nesfatin-1 IR is depicted in B. Red staining of the cytoplasm shows the presence of 
nesfatin-1 IR. Merged images of nesfatin-1 and DAPI staining are shown in C. Primary 
antibody pre-absorbed in 10 µg of nesfatin-1 and labeled with secondary antibody is 
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shown in D. No-primary antibody negative control, labeled only with secondary antibody 
is shown in E.  
2.3.3. Nesfatin-1 is Co-localized with GLP-1, GIP, CCK and PYY Immunoreactive 
Cells in the Intestine of Male C57BL/6J Mice 
 Fluorescence microscopy imaging at a magnification of 40X, showed the existence 
of NUCB2/nesfatin-1 (B, E, G, J) and the presence of GLP-1 (A), GIP (D), PYY (H) and 
CCK (K) immunopositive cells in duodenum. The figure below shows images of intestinal 
sections (small intestine – GLP-1, CCK and GIP; large intestine – PYY) collected from ad 
libitum fed male C57BL/6J mice. The tissues were incorporated in wax block, sectioned, 
fixed and stained over glass slides. Nuclei were stained blue with DAPI and 
immunopositive cells are stained in green and red, and co-localization is shown in yellow 
respectively (Figure 2.4). 
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Figure 2.4. Nesfatin-1 is co-localized with GLP-1, GIP, CCK and PYY immunopositive 
cells in the intestine of male C57BL/6J mice. Immunohistochemical staining of intestinal 
sections for nesfatin-1 IR is depicted in B, E, G and J. Red (B and E) and green staining 
(G and J) shows the presence of nesfatin-1 IR in the cytoplasm of enteroendocrine cells. 
Staining for PYY, CCK, GLP-1 and GIP IR is depicted in A, D, H and K. Green (A and D) 
and red staining (H and K) shows the presence of respective hormone IR in the cell 
cytoplasm as well. Merged images of nesfatin-1 with enteric hormones and DAPI are 
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shown in yellow in C, F, I and L. No-primary antibody negative control, treated only with 
secondary antibody was tested for all sections above (data not shown). 
2.3.4. Nesfatin-1 Upregulates Proglucagon mRNA and GLP-1 Secretion in STC-1 
Cells 
 Nesfatin-1 significantly upregulated proglucagon mRNA expression and GLP-1 
secretion into media in STC-1 cells (Figure 2.5). 
 
Figure 2.5. Treatment of STC-1 cells dose dependently with nesfatin-1 significantly 
upregulated proglucagon mRNA expression corresponding to 0.01, 0.1, 1 and 10 nM 
doses compared to control (A). Nesfatin-1 treatment also increased GLP-1 secretion into 
the media corresponding to 0.1, 1 and 10 nM doses in STC-1 cells (B). The mRNA 
expression data was normalized using β-Actin as the reference gene. Statistical analysis: 
One-way ANOVA with Tukey’s multiple comparison test (n = 8 wells/ treatment). Data 
pooled from two independent studies. 
2.3.5. Nesfatin-1 Upregulates GIP mRNA Expression and Secretion in STC-1 Cells 
 Nesfatin-1 significantly upregulated GIP mRNA expression and GIP secretion into 
media in STC-1 cells (Figure 2.6). 
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Figure 2.6. Treatment of STC-1 cells dose dependently with nesfatin-1 significantly 
upregulated GIP mRNA expression corresponding to 0.1, 1 and 10 nM doses compared 
to control (A). Subsequently, nesfatin-1 treatment increased GIP secretion into the media 
corresponding to 1 and 10 nM doses in STC-1 cells (B). The mRNA expression data was 
normalized using β-Actin as the reference gene. Statistical analysis: One-way ANOVA 
with Tukey’s multiple comparison test (n = 8 wells/ treatment). Data pooled from two 
independent studies. 
2.3.6. Nesfatin-1 Upregulates CCK mRNA Expression and Secretion in STC-1 Cells 
 Nesfatin-1 significantly upregulated CCK mRNA expression and CCK secretion 
into media in STC-1 cells (Figure 2.7). 
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Figure 2.7. Treatment of STC-1 cells dose dependently with nesfatin-1 significantly 
upregulated CCK mRNA expression corresponding to 1 and 10 nM doses compared to 
control (A). Subsequently, nesfatin-1 treatment increased CCK secretion into the media 
corresponding to 0.1, 1 and 10 nM doses in STC-1 cells (B). The mRNA expression data 
was normalized using β-Actin as the reference gene. Statistical analysis: One-way 
ANOVA with Tukey’s multiple comparison test (n = 8 wells/ treatment). Data pooled from 
two independent studies. 
2.3.7. Nesfatin-1 Downregulates PYY mRNA Expression and Secretion in STC-1 
Cells 
 Nesfatin-1 significantly downregulated PYY mRNA expression and PYY secretion 
into media in STC-1 cells (Figure 2.8). 
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Figure 2.8. Treatment of STC-1 cells dose dependently with nesfatin-1 significantly 
downregulated PYY mRNA expression corresponding to all doses tested, compared to 
control (A). Subsequently, nesfatin-1 treatment decreased PYY secretion into the media 
corresponding to 0.01 and 0.1 nM doses in STC-1 cells (B). The mRNA expression data 
was normalized using β-Actin as the reference gene. Statistical analysis: One-way 
ANOVA with Tukey’s multiple comparison test (n = 8 wells/ treatment). Data pooled from 
two independent studies. 
2.3.8. Subcutaneous Infusion of Nesfatin-1 Does Not Alter Glucose Handling in 
Male C57BL/6J Mice 
 
Figure 2.9. Administration of an oral load of 1 g/kg body weight D-glucose significantly 
increased blood glucose levels in both saline and in groups infused subcutaneously with 
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100 µg/kg body weight nesfatin-1. Statistical Analysis: Mann-Whitney U test (non-
parametric) (n = 6 animals/group). 
2.4. DISCUSSION 
 Nesfatin-1 is an anorexigenic peptide that was found in several tissues including 
the hypothalamic feeding centers, pancreas and stomach of mice [9, 12, 14]. Presence 
of NUCB2 mRNA expression is also detected in non-mammalian species including 
goldfish [180]. Nesfatin-1 suppresses gut ghrelin in goldfish [184], the first report on the 
effects of nesfatin-1 on a gastric hormone. More recently, the presence of 
NUCB2/nesfatin-1 in mice intestine was characterized by Zhang et al., [193]. They 
showed that NUCB2/nesfatin-1 IR cells are localized in the lower third and middle portion 
of the gastric mucosal gland and the submucous layer in the duodenum of Sprague 
Dawley (SD) rats and institute of cancer research (ICR) mice. Also, Western blot analysis 
showed higher NUCB2 protein expression in pancreas, stomach and duodenum. 
However, this was contradictory to what was reported earlier by Stengel et al., [14] 
wherein they did not find nesfatin-1 immunopositive cells in the intestine. The research 
characterizes nesfatin-1 expression in the gastric mucosa of stomach and found that 
NUCB2 mRNA expression is 10 fold higher in this region, compared to the total RNA 
extracts from rat brain. However, immunohistochemistry of intestinal sections showed 
absence of nesfatin-1 immunopositive cells in esophagus, colon and small intestine. 
Nonetheless, recent findings from our lab showed NUCB2 mRNA and protein expression 
in large and small intestine of male C57BL/6J mice, contradicting the earlier observation 
by Stengel et al., [15]. This is in line and supportive of previous observations by Zhang et 
al., showing presence of NUCB2/nesfatin-1 in the intestine of both mice and rats. The 
findings in this chapter reiterate and confirm the consensus that NUCB2/nesfatin-1 is 
present in the intestine and that nesfatin-1 modulates enteric hormone secretion in vitro. 
First, we showed that NUCB2 mRNA is expressed in STC-1 cells and found 
nesfatin-1 immunoreactivity in their cytoplasm. These results are highly indicative that 
intestinal enteroendocrine cells could be a source of endogenous nesfatin-1 in vivo. 
Secondly, immunohistochemical staining of intestinal sections from male C57BL/6J mice 
showed NUCB2/nesfatin-1 immunoreactivity. Nesfatin-1 immunopositive cells, 
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specifically were observed in the crypts of the intestinal villi and in the submucosa being 
mainly concentrated around the Brunner’s glands and in blood vessels surrounding the 
connective tissue. This is consistent with the observation by Zhang et al.,[193] wherein 
they found NUCB2/nesfatin-1 IR in the Brunner’s glands of duodenum. These glands are 
primarily confined to the duodenal bulb. The main function of these glands are to produce 
an alkaline secretion containing bicarbonate and mucus to protect duodenum from the 
acidic chime, maintain an alkaline environment for proper action of intestinal enzymes 
and, to lubricate the intestinal walls. The presence of nesfatin-1 IR here highlights its 
potential role in enzyme activation, nutrient absorption and preservation of intestinal walls 
which warrants further consideration [193]. Besides enzymes, intestine is a major 
endocrine tissue, giving rise to a spectrum of hormones that has important functions in 
feed intake and energy metabolism as discussed earlier in section 1.2.2. Since we found 
nesfatin-1 IR in intestinal sections (both small and large intestine) and since our previous 
findings clearly shows its protein and mRNA expression in the same region [15] we 
hypothesized that nesfatin-1 could modulate intestinal enteric hormone secretion. 
As a start point to address this hypothesis, immunohistochemical analysis of 
intestinal sections from ad libitum fed male C57BL/6J mice showed nesfatin-1 IR to be 
co-localized with GLP-1, GIP and CCK IR in small intestine and with PYY IR in large 
intestine. The co-localization was found distributed uniformly throughout the submucosa 
and in the crypts of villi. However, not all the cells observed under a given area of the 
section showed co-localization. There were some cells that were immunopositive for 
nesfatin-1 but not for the respective intestinal hormones. This is expected as 
enteroendocrine cells are capable of synthesizing and secreting all major enteric 
hormones tested in this chapter i.e. GLP-1, GIP, CCK and PYY depending on the 
nutritional status and nutrient availability of animal in vivo. Although, they are classified 
cytochemically as K, L and I cells, this classification is based on the major hormones they 
secrete and shouldn’t be inferred that the cells secrete that specific hormone alone. 
Nonetheless, in all sections nesfatin-1 immunopositive cells were found in the aforesaid 
region consistently. The colocalization of nesfatin-1 with intestinal hormones suggests 
possible local (autocrine/paracrine) or endocrine actions of nesfatin-1 on these peptides. 
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 Thirdly, in vitro studies involving treatment of STC-1 cells dose-dependently with 
nesfatin-1 showed increase in GLP-1, GIP and CCK mRNA expression and secretion into 
media. The study also showed that nesfatin-1 decreased PYY mRNA expression and 
secretion into media by RT-qPCR and immunoassays. From a food intake and appetite 
standpoint, previous research has classified GLP-1, GIP and CCK as anorexigenic 
peptides and PYY as orexigenic [93, 139, 147]. Our current findings show that nesfatin-1 
is directly modulating, in that it increases the expression and secretion of anorexigenic 
intestinal hormones (GLP-1, GIP and CCK) and it suppresses the expression and 
secretion of orexigenic hormone PYY. Also, with regard to insulin secretion, previous 
research have shown incretins and CCK to be insulinotropic and PYY to be insulinostatic 
[6-8, 16]. Results from in vitro studies shows that nesfatin-1 increases insulinotropic and 
suppresses insulinostatic intestinal hormones. These novel results reveal yet another 
extra-pancreatic function of NUCB2/nesfatin-1 in peripheral tissues, besides the reported 
insulinotropic action [5]. The results also highlight an indirect mechanism of nesfatin-1 
action on insulin secretion, by modulating the expression/secretion levels of 
insulinotropic/insulinostatic enteroendocrine hormones. 
Analyzing the data points for the results from in vitro studies, the nesfatin-1 effect 
on GLP-1 expression and secretion is highly dose-dependent, with the upregulation quite 
apparent between 0.1 and 10 nM when compared to controls. One common concern 
regarding the RT-qPCR data on the relative mRNA expression of proglucagon is the 
specificity of the primer used, as proglucagon gene besides GLP-1, also encodes GLP-
2, oxyntomodulin and glicentin in intestinal L cells in vivo. To negate this, the primer pairs 
used in the study is highly specific for the GLP-1 coding region of proglucagon gene and 
an upregulation in this region of the mRNA alone is the outcome of our dose-dependent 
nesfatin-1 treatment data. The dose-dependency on GIP expression and secretion is also 
clear, with nesfatin-1 having a stimulatory effect at higher doses of 1 and 10 nM tested. It 
will be interesting to see the extrapolation of this result in particular in vivo, as GIP 
secretion from K cells is modulated more by the rate of nutrient absorption in intestine 
rather than nutrient availability [113]. Therefore, nesfatin-1 modulation of GIP secretion in 
vivo is expected to be difficult to capture with studies on feed availability alone and might 
require a study testing various diets with differential rates of nutrient absorption.  
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Nesfatin-1 effect on CCK secretion also is dose-dependent with maximum 
expression and secretion being observed corresponding to the highest doses tested i.e. 
1 and 10 nM. Though this effect is on total CCK in media, its effect on CCK-33 which is 
the predominant circulating form [134] or CCK-8 [139] that induces satiety upon infusion 
remains to be elucidated. Interestingly, the suppressive effect of nesfatin-1 on PYY 
expression and secretion is not dose-dependent at least at the level of 
translation/secretion. PYY is predominantly expressed in the large intestine, and in cell 
studies nesfatin-1 suppressed PYY mRNA at all doses tested. However, the 
downregulation was significant corresponding only to two doses at the level of secretion 
i.e. 0.01 and 0.1 nM. Our immunohistochemistry data shows co-localization of nesfatin-1 
IR with PYY. On a comparative basis, the number of cells positive for co-localization is 
lesser than those compared to GLP-1 and CCK co-localization. As our in vitro data 
suggests opposite actions for nesfatin-1 and PYY, whether or not they are secreted in 
distinct cytoplasmic vesicles similar to nesfatin-1 and ghrelin in X/A like cells remains to 
be elucidated. Also considering the time food takes to reach large intestine in vivo and 
that intestinal PYY increases transit time of ingested food [237], the role of nesfatin-1 in 
these cells is likely to be paracrine wherein it stimulates other enteric hormone secretion 
upon secretion and autocrine wherein it inhibits PYY secretion at least immediately after 
an ingested meal. 
Nesfatin-1 at an effective dose of 0.1 and 1 nM was reported to upregulate 
preproinsulin mRNA expression and glucose-dependent insulin release from MIN6 cells. 
It also stimulated insulin release from isolated mouse islets corresponding to 0.01, 0.1 
and 1 nM doses [5]. These data are comparable with results from in vitro studies in STC-
1 cells, wherein nesfatin-1 at similar doses of 0.1, 1 and 10 nM doses was effective in 
stimulating GLP-1, GIP, CCK secretion and inhibiting PYY secretion. In in vivo studies, 
the circulating glucose levels were significantly elevated in both saline and nesfatin-1 
infused mice in response to an oral load of glucose, showing normal glucose handling in 
both groups. This result verifies that the glucose administration was effective, and there 
are no differences in glucose levels due to subcutaneous nesfatin-1 infusion alone. We 
originally planned and executed ELISAs for enteric hormones. However, due to low 
volumes of serum obtained and used, the ELISA results were not usable (most values 
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below low standard). Due to this setback in obtaining secreted levels of hormones, we 
are now planning intestinal hormone gene/protein expression in major peripheral tissues: 
stomach, pancreas, liver, and intestine, using the tissues collected at the end of the 
OGTT. This analysis is expected to partly provide the missing information on synthesis of 
intestinal hormones. Osmotic mini-pumps are reliable tools to infuse peptides of interest, 
and it was used previously for successfully administering and elevating nesfatin-1 levels 
in rats [13].  In order to ensure that circulating nesfatin-1 levels are indeed increased in 
response to continuous infusion using the mode selected, we will measure nesfatin-1 in 
vivo in control and peptide treated mice.  
2.5. CONCLUSIONS 
 This research provides strong evidence for NUCB2/nesfatin-1 expression in 
intestine thus strengthening previous observations [15, 193]. It also for the first time 
reports the co-localization of nesfatin-1 with CCK, PYY, GLP-1 and GIP immunopositive 
cells in mouse intestine. The studies carried out characterizes STC-1 cells as 
NUCB2/nesfatin-1 expressing cells and that nesfatin-1 dose-dependently modulates 
hormone secretions from this cell line. This highlights STC-1 cells as useful in vitro models 
for studying nesfatin-1 biology, besides the secretion kinetics of intestinal hormones. The 
in vivo studies pertaining to this objective is currently in progress and will be completed 
soon. Results from them will provide a more complete picture whether or not nesfatin-1 
modulates enteric hormone secretion in vivo via osmotic pump infusion in mice. Nesfatin-
1 has been researched for its role on insulin secretion and satiety. It is becoming 
increasingly apparent that both central and peripheral nesfatin-1 have functions beyond 
these two, and this chapter is a major contribution in line with this notion. The results that 
nesfatin-1 is co-expressed with major intestinal hormones and that it modulates their 
secretion opens up a lot of possibility for testing new biological actions of this peptide.  
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TRANSITION 
 
The following chapter focuses on objectives 3-4: Insulinotropic action of a NUCB1 
encoded Nesfatin-1-Like Peptide (NLP). Endogenous NUCB1 mRNA in pancreatic islets 
of C57BL/6J mice and in MIN6 cells by RT-qPCR and gel electrophoresis were detected. 
Subsequently, NUCB1 immunoreactivity was co-localized with insulin in islets and MIN6 
cells and was detected by immunocytochemistry. This chapter will elaborate the studies 
carried out, major techniques used for answering specific research question mentioned 
above and the results obtained. This is followed by a discussion and conclusion of major 
findings pertaining to the research question. At the time of writing this chapter, nothing is 
known about a nucleobindin-1 (NUCB1) encoded bioactive peptide. 
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CHAPTER 3 
 INSULINOTROPIC ACTION OF A NUCB1 ENCODED NESFATIN-1-LIKE PEPTIDE 
(NLP) 
3.1. INTRODUCTION 
 Nesfatin-1 (NEFA/nucleobindin-2-encoded satiety and fat-influencing protein-1) is 
an 82 amino acid peptide encoded in the N-terminal region of its precursor, nucleobindin-
2 (NUCB2) [9, 15]. It was predicted that NUCB2 is processed by prohormone convertases 
(PC) to form nesfatin-1 [9]. Administration of the full-length nesfatin-1 or its 30 amino acid 
mid-segment (M30), considered its bioactive core, reduces food intake and fat mass in 
rodents [9, 13, 182], and food intake in pigs [238] and fish [180, 184]. We, and others 
have identified nesfatin-1 immunoreactivity in the pancreatic islet beta cells of rats, mice 
[10, 12, 13] and humans [10] and found an insulinotropic effect for this peptide in vitro [5, 
10] and in vivo [13]. Nesfatin-1 increases glucose-stimulated insulin secretion from β cells 
by direct action involving Ca2+ influx through L-type calcium channels [239]. Nesfatin-1 is 
emerging as NUCB2-derived multifunctional peptide affecting major organ systems in 
vertebrates [240]. When originally discovered, nucleobindin-2 was given its name due to 
its very high sequence similarity with another secreted protein, nucleobindin-1 (NUCB1). 
Both NUCB1 and NUCB2 are homologous multi-domain Ca2+ and DNA binding proteins 
encoded in two unlinked genes. Human NUCB1 and NUCB2 exhibit 62% amino acid 
sequence identity and are remarkably conserved within the nesfatin-1 region between 
humans and zebrafish [19, 240, 241]. NUCB1 has been widely reported within the 
nucleus, endoplasmic reticulum and cytoplasm of stomach, intestine, adrenal glands, 
pituitary, ovary and testis [219].The N-terminal golgi retention domain allows NUCB1 to 
be targeted to various cellular components and its deletion renders the localization of 
NUCB1 to the cytoplasm [10, 230, 231]. The endogenous expression profile of NUCB1 
was characterized recently by immunofluorescence staining, showing NUCB1 localization 
in the endocrine pancreas along with insulin, glucagon, somatostatin, ghrelin and 
pancreatic polypeptide immunopositive cells [208]. NUCB1 has been shown to play a 
crucial role in the maintenance of Ca2+ homeostasis, and it interacts with G proteins and 
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cyclooxygenases [20, 217]. In addition, oh-I and colleagues [9] indicated that both NUCB1 
and NUCB2 are secreted proteins arising from two homologous genes arising from a 
single EF-hand ancestor. Therefore, whether NUCB1 encodes a biologically active 
nesfatin-1-like peptide remains unknown. 
 Is there a nesfatin-1-like peptide encoded in NUCB1? Does it possess PC 
cleavage sites? Is this peptide biologically active? In silico analysis found that a nesfatin-
1-like peptide (NLP) is indeed present in the NUCB1. This research, for the first time, 
reports an insulinotropic activity for synthetic NLP. The endogenous NUCB1 protein 
expression in major peripheral tissues in response to feed availability was also 
determined. These findings provide important information on a new, naturally occurring 
insulinotropic peptide. 
3.2. MATERIALS AND METHODS 
3.2.1. In Silico Analysis 
NUCB1 and NUCB2 sequences were obtained from the GenBank 
(http://www.ncbi.nlm.nih.gov/genbank/), and aligned using ClustalW 
(http://www.clustal.org/clustal2/) and eBioX (http://www.ebioinformatics.org/ebiox/) 
software. Percentage identity between sequences were ascertained using ClustalW2 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/). SignalP 4.1 Server 
(http://www.cbs.dtu.dk/services/SignalP/) was used for predicting the signal peptide 
region in NUCB1. PC cleavage sites and putative peptides encoded within NUCB1 were 
predicted by the Prop 1.0 Server (http://www.cbs.dtu.dk/services/ProP/) and 
NeuroPred™ (http://neuroproteomics.scs.illinois.edu/neuropred.html). 
3.2.2. Cell Culture 
 MIN6 cells used in the study were a kind gift from Dr. Robert Tsushima (York 
University, Toronto). MIN6 cells are derived from transgenic founder mice that developed 
pancreatic insulinoma [242]. These cells have the morphological characteristics of β cells 
and exhibit glucose-inducible insulin secretion, comparable to normal cultured mouse 
islets cells. MIN6 expresses high levels of liver type glucose transporter (GT) mRNA, 
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suggesting the importance of transporter in glucose-stimulated insulin secretion. 
Treatment of MIN6 with Interferon-γ induces high levels of major histocompatibility 
complex (MHC) class I antigen on the cellular surface, emphasizing that the cells retain 
the physiological characteristics of β cells [242]. MIN6 also have been reported to have 
the innate ability to form cell clusters [243]. Given the study that monolayer cultures of 
cells have less GSIS, and that cell to cell contact is highly important for GSIS, MIN6 are 
suitable immortalized cell lines to analyze the molecular mechanisms by which β cells 
regulate insulin secretion in response to varying concentrations of extracellular glucose. 
 Cells were cultured in Dulbecco’s Modified Eagles Medium (DMEM, Invitrogen, 
Catalog #11995-040) supplemented with 10% fetal bovine serum (FBS, Invitrogen, 
Catalog# 12484), penicillin (100 U/mL), streptomycin (100 µg/mL) (Invitrogen, Catalog# 
15140-122) and 2-Mercaptoethanol (Life Technologies, Catalog# 21985-023). Cells were 
incubated at 37°C and 5% CO2 culture conditions in a humidified incubator to promote 
growth. Cell culture media was changes every 48 hours after washing twice with 
Dulbecco’s Phosphate-Buffered Saline (DPBS, Life Technologies, and Catalog # 14190-
250). The cells were sub-cultured once they reached 85-90% confluency using 0.25% 
trypsin-EDTA (Life Technologies, Catalog# 25200-056) as described earlier [53]. 
3.2.3. Detection of Endogenous NUCB1 Protein Expression in MIN6 cells and in 
Mouse Pancreatic Islets 
 MIN6 cells were cultured in a LabtekTM Chamber Slide SystemTM (Nalge Nunc, 
New York). Cells were washed with 1X phosphate buffer saline (PBS), fixed in 4% 
paraformaldehyde, permeabilized using 0.3% Triton-X (Bioshop, Catalog# TRX777), and 
incubated in blocking buffer containing 10% goat serum. For immunohistochemical 
studies, pancreas was collected from male C57BL/6J mice (Charles River, Quebec, 
Canada) cared under the Canadian Council of Animal Care guidelines, as approved by 
the University of Saskatchewan Animal Care Committee. Mice were euthanized under 
deep carbon dioxide inhalation followed by cardiac puncture, pancreas collected and fixed 
in 4% formaldehyde overnight at 4o C, processed, embedded in paraffin sections of 4 µm 
thickness were prepared. Cells and slides were then incubated with primary antibody at 
4o C overnight, followed by secondary antibody incubation for 4 hours at room 
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temperature. Primary antibodies used were: rabbit anti-nesfatin-1 (Phoenix 
Pharmaceuticals, 1:500 dilution, Catalog# H-003-22), rabbit anti-nucleobindin 1 (Abcam, 
1:500 dilution, Catalog# ab23387), guinea pig anti-insulin (Abcam, 1:100 dilution, 
Catalog# ab 7842) or mouse anti-glucagon (Abcam, 1:200 dilution, Catalog# K79bB10). 
The respective secondary antibodies were goat anti-rabbit Texas Red® IgG (Vector 
Laboratories, Red-Nesfatin-1, 1:100 dilution, Catalog# TI-1000), goat anti-guinea pig 
FITC IgG (Abcam, Green-Insulin, 1:200 dilution, Catalog# ab6904) and goat anti-mouse 
FITC IgG (Abcam, Green-Glucagon, 1:200 dilution, Catalog# ab6785). The slides were 
washed in 1X PBS and mounted using Vectashield® mounting medium containing the 
nuclear dye DAPI (Blue; Vector Laboratories). Tissue and cells were analyzed under a 
BX51 microscope (Olympus, Ontario, Canada), images were captured using an Olympus 
DP70 camera and were assessed using the DP controller program. 
3.2.4 Qualitative Analysis – Expression of NUCB1 mRNA in MIN6 Cells and in 
Mouse Pancreas 
 Cells were grown as described in section 3.2.3.1. Upon confluence the total RNA 
was extracted as described in section 2.2.4.1. Pancreas was collected and processed 
from ad libitum fed male C57BL/6J mice by euthanizing the animals using cervical 
dislocation. The collected tissue was dissected and stored in RNALater™ (Life 
Technologies, Catalog# AM7020). The tissues were then thawed for 10 minutes at room 
temperature and transferred to new tubes containing TRIzol® regent. This was followed 
by total RNA extraction using TRIzol method as described in section 2.2.4.1. Synthesis 
of cDNA was conducted using iScript™ Reverse Transcription Supermix as described in 
section 2.2.4.2. The cDNA synthesized was used as template to determine the qualitative 
expression of NUCB1 in MIN6 cells and mouse pancreas. The primer sequences were 
obtained from National Center for Biotechnology Information Gene Bank (NCBI) and the 
primers were synthesized using Primer-BLAST™, primer designing tool from NCBI 
(www.ncbi.nlm.nih.gov/tools/primer-blast/). The GenBank accession number is given 
under each gene. The forward and reverse primers are provided in Table 3.1. 
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Table 3.1. Primer Pairs for mouse NUCB1 and β-Actin with Respective Annealing 
Temperatures 
Gene Forward (5’ – 3’) Reverse (3’ – 5’) Amplico
n Size 
(bp) 
Annealing 
Temperature 
Mouse NUCB1 
(NM_001163662.1) 
 
ggacctcagctagggg
gtgta 
Agcctaccctaactccca
gg 
96 60°C 
Mouse β-Actin 
(NM_007393.3) 
 
ccactgccgcatcctctt
cc 
 
ctcgttgccaatagtgatg
ac 
 
77 60°C 
 
 Primers were validated and optimized for high primer efficiency and annealing 
temperatures. The primers were then used for conducting qualitative PCR. The PCR was 
conducted on a thermo cycler (Bio-Rad, Canada) for 35 cycles. The samples were stored 
at -20° C until gel electrophoresis. The components of the mastermix are provided in 
Table 2.4. The components for the qualitative PCR are provided in Table 2.5. The 
reaction protocol used is described in Table 3.2 below. 
Table 3.2. Optimized PCR conditions with respective annealing temperatures for 
NUCB1 and β-Actin. (Step 1: Initial Activation; Step 2: Denaturation; Step 3: 
Annealing; Step 4: Elongation; Step 5: Infinite Hold) 
 Step 1 Step 2 Step 3 Step 4 Step 5 
Temperature 95°C 95°C 60°C 73°C 4°C 
Time 5 minutes 30 seconds 30 seconds 30 seconds Infinite Hold 
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Following PCR, the samples were run on 1% agarose gel as described in section 
2.2.4.2. The images were captured using GelDoc™ EZ system (Bio-Rad, Canada). 
3.2.5. Nesfatin-1-Like Peptide Effects on Preproinsulin mRNA Expression and 
Insulin Secretion 
Static incubation study was conducted to determine the effects of dose-dependent 
synthetic NLP treatment on preproinsulin mRNA expression in MIN6 cells. Cells were 
cultured as described in section 3.2.2. Cells at 2 x 105 cells per well density were seeded 
with 1 mL DMEM (25 mM glucose) in 24-well plates. On the day of study, medium was 
removed and cells were washed twice with PBS. The cells were then treated with 1 mL 
of DMEM containing 0 (control), 0.001, 0.01, 0.1, 10, 100 or 1000 nM rat synthetic NLP 
(VPVDRAAPHQEDNQATETPDTGLYYHRYLQEVINVLETDGHFREKLQAANAEDIKSG
KLSQELDFVSHNVRTKLDEL; Abgent Technologies, California) based on a 77 amino 
acid predicted sequence within the rat nucleobindin 1 (GenBank # AAI00644.1). The 
peptide is >95% pure and the mass and purity were confirmed by LC-MS. The culture 
media was isolated to evaluate the insulin content by insulin ELISA. Total RNA extraction 
and preproinsulin relative mRNA expression was determined as described below. The 
studies were repeated twice and data from these independent studies were pooled. Cells 
were collected from the study to assess the relative mRNA expression of preproinsulin. 
Total RNA extraction using the TRIzol method was carried as described in section 2.2.4.1. 
The purity of RNA was determined using Nandrop™ 2000C. The RNA sample is stored 
in -80° C until further required. cDNA was synthesized using iScript cDNA synthesis kit 
as described in section 2.2.4.2. The samples were stored at -20°C until used as a 
template for RT-qPCR. The relative mRNA expression of preproinsulin was conducted 
using iQ™ SYBR® green supermix for 35 cycles as described in section 2.2.3.3. Forward 
and reverse primers for preproinsulin were synthesized as described in section 3.2.4.3 
and are provided in Table 3.3 below. β-Actin was used as internal control and the details 
are described in Table 3.1. 
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Table 3.3. Primer Pair of Mouse Preproinsulin with Respective Annealing 
Temperature 
Gene Forward (5’ – 3’) Reverse (3’ – 5’) Amplico
n Size 
(bp) 
Annealing 
Temperature 
 
Mouse 
Preproinsulin 
(NM_008386.3) 
 
 
ggcttcttctacacacc
ca 
 
cagtagttctccagctgg
ta 
 
182 
 
59°C 
 
The relative gene expression data were obtained after normalizing the data to β-
Actin using Pfaffl method [155]. 
 The insulin secretion into the media was measured using mouse ultrasensitive 
insulin ELISA kit (ALPCO, Catalog# 80-INSMS-E01) and Insulin-125I RIA kit (MP 
Biomedicals™, Catalog# 07RK547) according to the manufacturer’s instructions. The 
limit of assay sensitivity was 0.06 ng/mL (ELISA) and 1 ng/mL (RIA). The detectable range 
for the kits were from 0.188 – 6.9 ng/mL and 0.1 – 25 ng/mL respectively. The plates were 
read using SoftMAX® 190 microplate reader equipped to read absorbance at 450nm 
(Molecular Devices, USA). The amount of immunoreactive material was determined using 
non-linear regression curve-fit, which was used to quantify and compare the 
concentration of insulin secretion in media samples. 
3.2.6. Is a Specific Amino Acid Organization Critical for the Biological Activity of 
Nesfatin-1-Like Peptide? 
 There are two reasons for this study. The first objective was to determine whether 
the NLP sequence is critical for its insulinotropic action. The second aim was to test 
whether any peptide that shares the same amino acids and length, but highly dissimilar 
amino acid arrangement could also elicit the same response. In order to test these, we 
decided to use a scrambled peptide that has 77 amino acids that constitute the NLP, but 
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not in the order seen in NLP. A 79 amino acid (including the two amino acids constituting 
the cleavage site) scrambled peptide was designed using the Sequence Manipulation 
Suite™ (www.bioinformatics.org/sms2/) and PepControls™ 
(bioware.ucd.ie/~cyclops/.../PepControls.../1.3/.../control_peptides.html) (University of 
California, Davis) online tool. The peptide scramble 
(PDSRSDDGSPSVQLQDYALIADAEVTLTHIELFGSPQNATKLLNKTERLRFLKVVRGK
HRENVVATEHYQAQKYPEEDE) with the lowest similarity to the NLP amino acid 
sequence and with low synthesis issues was selected. The peptide synthesized (Pacific 
Immunology, California, USA) was >95% pure and the mass and purity was confirmed 
by LC-MS. 
For static incubation studies, MIN6 cells at 2 x 105 cells per well density were 
seeded in 1 mL DMEM (25 mM glucose) in 24-well plates. On the day of study, medium 
was removed and cells were washed twice with PBS. The cells were then treated with 1 
mL of DMEM containing 10 and 100 nM rat synthetic nesfatin-1-like peptide, 10 and 100 
nM of scrambled peptide and 1 nM synthetic rat nesfatin-1 as a positive control. After 1 
hour incubation, media samples were collected and insulin content was measured as 
described in section 3.2.5.4. The cells were collected and total RNA extracted, cDNA 
synthesis followed by RT-qPCR for preproinsulin mRNA expression was carried out as 
described under 3.2.5. The studies were repeated twice and data from these independent 
studies were pooled. 
3.2.7. Quantitative Analysis of Endogenous NUCB1 Protein Expression in ad 
libitum Fed and Food Deprived Mice 
3.2.7.1. Animals 
 Age matched 4 months old C57BL/6J mice (Charles River Laboratories, Quebec, 
Canada) were housed in a temperature-controlled vivarium with 12h/12h dark and light 
cycles. Animals had ad libitum access to standard mouse chow and water. All protocols 
strictly adhered to the guidelines of the Canadian Council for Animal Care, and were 
approved by the University of Saskatchewan Animal Research Ethics Board. 
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3.2.7.2. Western Blot Analysis 
 For characterizing the endogenous levels of nucleobindin-1 (NUCB1), 4 months 
old C57BL/6J male mice (Charles River Laboratories, Canada) were divided into two 
groups; fed (n = 6) and unfed (n = 6) group respectively. The unfed group were fasted for 
24 hours, while the fed group had ad libitum access to standard mouse chow and water 
during the same time. After 24 hour differential feed availability, all animals were 
euthanized by cervical dislocation. Dissected whole stomach, pancreas, liver, small and 
large intestine were homogenized in T-PER® tissue protein extraction reagent 
(Thermoscientific, Catalog# 78510) followed my measurement of protein concentration 
by Bradford assay. The samples were prepared in 1X laemmli buffer containing 0.2% 2-
mercaptoethanol (Bio-Rad, Catalog# 161-0737 and -0710) and subsequently were boiled 
at 95°C for 5min followed by vortexing. The whole sample volume (20 µL) each containing 
50 µg protein was loaded and run in a Mini-PROTEAN® TGX™ 8-16% gradient gel (Bio-
Rad, Catalog# 456-1104). After separation the proteins were transferred to a 0.2 µm 
BioTrace™ nitrocellulose membrane (PALL Life Sciences, Catalog# 27377-000) and then 
membrane was blocked in 1X RapidBlock™ solution (aMReSCO, Catalog# M325). 
NUCB1 protein detection was performed using rabbit antiserum directed against mouse 
NUCB1 (Custom Antibody, Pacific Immunology, Catalog# 1312-PAC-02) diluted 1:1000 
and β tubulin protein was detected by use of rabbit antiserum directed against mouse β 
tubulin (Cell Signaling Technology®, Catalog# 2146) diluted 1:2000. As secondary 
antibody, goat anti-rabbit IgG (H+L) HRP conjugate (Bio-Rad, Catalog# 170-6515) diluted 
1:3000 was used. For protein visualization the membrane was incubated for 5min in 
Clarity™ Western ECL substrate (Bio-Rad, Catalog# 170-5061) and imaged using 
ChemiDoc™ MP imaging system (Bio-Rad, Catalog# 170-8280) with chemiluminescence 
detection. Membrane stripping in between protein detection was conducted using 
Restore™ PLUS Western blot stripping buffer (Thermoscientific, Catalog# 46430). 
Precision plus protein™ Dual Xtra standards (Bio-Rad, Catalog# 161-0377) were used 
as molecular weight markers. 
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3.2.8. In Vivo Effects of NLP on Dark and Light Phase Feed Intake 
 Animals were housed as described in section 3.2.7.1. Twenty four hours prior to 
the study, animals were grouped into two: saline-treated groups (n = 6) and NLP-treated 
groups (n = 6). On the day of the experiment, osmotic pumps (ALZET®, Catalog# 2001D) 
were filled either with saline or 100 µg/kg body weight NLP dissolved in saline, as per 
manufacturer’s instruction. Subsequently, the pumps were implanted subcutaneously into 
animals as described in section 2.2.5 earlier. The feed intake was monitored by 
measuring the weight of food for all animals at four time point i.e. 1 AM (+6 hour dark 
phase), 7 AM (+12 hour dark phase), 1 PM (+6 hour light phase) and 7 PM (+12 hours 
light phase) respectively. To maintain consistency the timing and duration of experiment, 
and sample measurement were kept constant for all animals.  
3.2.9. Statistical Analysis 
 Analysis of the quantified RT-qPCR and immunoassays data were conducted 
using One-way ANOVA followed by Tukey’s multiple comparison test. IBM SPSS™ 
version 21 (IBM., USA) as used for statistical analysis and GraphPad Prism version 5 
(GraphPad Inc., USA) was used for generation of graphs. Significance was assigned 
when p<0.05. All data are expressed as mean ± standard error of mean (SEM). 
3.3. RESULTS 
3.3.1. In Silico Analysis of NUCB1 
 A nesfatin-1-like region is present within the NUCB1. The nesfatin-1-like peptide, 
especially its putative bioactive core (Figure 3.1 - A) exhibited very high similarity with 
nesfatin-1 encoded in NUCB2 (Figure 3.1 - B). The bioactive cores of 82 amino acid 
nesfatin-1 and 77 amino acid NLP have 76.6% amino acid sequence identity in mouse. 
The bioactive core region (M30) within the NUCB1 presented a greater degree of 
similarity. A signal peptide cleavage site is present at position 25 (Arginine) and 26 
(Valine) in the NUCB1 sequence. Analysis of NUCB1 using the ProP 1.0 Server and 
NeuroPred™ tools revealed potential proprotein convertase cleavage site at Lys-Arg 
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(KR), forming a 77 amino acid nesfatin-1-like peptide. Due to its high similarity to nesfatin-
1 from NUCB2, we named this protein nesfatin-1-like peptide (NLP). 
 
 
Figure 3.1. A. Scheme showing the signal peptide, nesfatin-1-like peptide region (1-77), 
and the putative processing sites (KR) in mouse NUCB1 sequence. NUCB1 encoded 
NLP sequences from various species. The putative bioactive core region is marked. B. 
Sequence comparison of NUCB2 encoded nesfatin-1 showing the bioactive core. 
GenBank Accession numbers of sequences used: Rattus norvegicus (NUCB1, 
AAI00644.1; NUCB2, AAH61778.1), Mus musculus (NUCB1, AAH72554.1; NUCB2, 
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AAH10459.1), Homo sapiens (NUCB1, NP_006175.2; NUCB2, NP_005004.1), Danio 
rerio (NUCB1, NP_001038928.1; NUCB2A, NP_958901.1; NUCB2B, NP_958887.1), and 
Xenopus tropicalis, (NUCB1, AAH67991.1; NUCB2, AAH90107.1). 
3.3.2. NUCB1 mRNA Expression in MIN6 cells and Mouse Pancreas 
 A band of approximately 96 bp of NUCB1 mRNA was detected (Figure 3.2) in 
MIN6 cells and mouse pancreas. The negative control reaction resulted in no bands. 
 
Figure 3.2. Gel electrophoresis image showing the presence of NUCB1 mRNA in MIN6 
cells and mouse pancreas. The amplicon size of the band was approximately 96 base 
pairs. 
3.3.3. NUCB1 and NUCB2 Immunoreactivity in Pancreatic Islets and MIN6 Cells 
NUCB1 immunoreactivity was detected in MIN6 cells (Figure 3.3 - C) and mouse 
pancreatic islet beta cells (Figure 3.4; C-D). Co-localization (Figures 3.3; E-F, 3.4 - E) 
of NUCB1 (Figures 3.3 C, 3.4; C-D) and insulin (Figures 3.3; A-B, 3.4 - E) was observed 
in MIN6 cells and pancreatic islets. No co-localization of NUCB1 and glucagon was found 
in alpha cells (Figure 3.4 - F). 
~96 bp 
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Figure 3.3. Photomicrographs showing insulin (A-B; green), NUCB1 (C; red), NUCB2 (D; 
red), and co-localization (yellow) of NUCB1 (E) or NUCB2 (F) with insulin in MIN6 cells. 
Scale bar = 50 µm. 
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Figure 3.4. Photomicrographs showing insulin (A; green), glucagon (B; green), NUCB1 
(C-D), co-localization of NUCB1 with insulin (E; yellow; cells pointed by arrows), and lack 
of co-localization of NUCB1 and glucagon (F) in the pancreatic islets of mice. No NUCB1 
staining was detected in secondary antibody alone controls (G).  Scale bar = 50 µm. 
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3.3.4. NLP Stimulates Insulin Release from MIN6 Cells 
NLP (10 and 100 nM) stimulated preproinsulin mRNA expression (Figure 3.5 - A) 
and insulin release (Figure 3.5 - B) from MIN6 cells at 1 hour post-incubation. No effects 
were detected for other doses of NLP tested (Figures 3.5; A-B). 
 
Figure 3.5. Nesfatin-1-like peptide (NLP) enhances preproinsulin mRNA expression (A), 
and stimulates insulin secretion (B) from MIN6 cells at 10 and 100 nM (significance 
denoted by *) compared to no treatment controls and other doses tested. Data are 
presented as mean + SEM. n = 8-12 wells pooled from three different studies. 
3.3.5. A Scrambled Peptide Based on the NLP Sequence had no Effect on 
Preproinsulin mRNA Expression and Insulin Secretion in MIN6 Cells 
 NLP (100 nM) stimulated preproinsulin mRNA expression (Figure 3.6 - A) and 
insulin release (10 and 100 nM) (Figure 3.6 - B) from MIN6 cells at 1 hour post incubation. 
No effects were detected for similar doses of scrambled peptide. Nesfatin-1 (1 nM) 
stimulated both preproinsulin mRNA expression and insulin secretion into media in MIN6 
cells. 
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Figure 3.6. Nesfatin-1-Like peptide (NLP) and nesfatin-1 enhances preproinsulin mRNA 
expression. However, a scrambled peptide to NLP did not elicit any effects on 
preproinsulin mRNA (A). NLP and nesfatin-1 stimulates insulin secretion (B) from MIN6 
cells at 10, 100 nM and 1 nM respectively (significance denoted by *) compared to no 
treatment control. Data are presented as mean + SEM. n = 8 wells/ pooled from two 
different studies. 
3.3.6. Fasting increases NUCB1 Protein Expression in Mouse Liver 
  Mice fasted for 24 hours had a significant increase in NUCB1 protein expression 
in liver when compared to controls (Figure 3.7 – A). However, no changes in expression 
were observed in pancreas (Figure 3.7 – B) and stomach (Figure 3.7 – C). 
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Figure 3.7. Food deprivation for 24 hours results in a significant increase in NUCB1 
protein expression in liver of C57BL/6J mice when compared to controls (A). No changes 
were observed in pancreas (B) and stomach (C). The band intensities were quantified 
using ImageJ™ software and were normalized to β-Tubulin. Data represented as mean 
+ SEM. n = 6 animals/group. 
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3.3.7. Osmotic Pump Infusion of NLP had no Effect on Dark and Light Phase Feed 
Intake in Mice 
 No changes in dark and light phase feed intake were observed in C57BL/6J mice 
when 100 µg/kg body weight NLP was infused using osmotic pumps (Figure 3.8). 
 
Figure 3.8. Subcutaneous infusion of 100 µg/kg body weight NLP using osmotic pump in 
male C57BL/6J mice had no effect on feed intake over a period of 24 hours, when 
compared to saline treated group. Data are represented as mean + SEM. n = 6 
mice/group. 
3.4. DISCUSSION 
In the original article that reported nesfatin-1, Oh-I and colleagues [9] indicated 
that both NUCB1 and NUCB2 are secreted proteins arising from two homologous genes 
arising from a single EF-hand ancestor. Whether NUCB1 encodes a biologically active 
nesfatin-1-like peptide remains unknown. Here, we report the first detailed sequence 
analysis showing the presence of a nesfatin-1-like peptide in NUCB1, its presence within 
the endocrine pancreas, and an insulinotropic role for NLP. Our analysis of the NUCB1 
sequence using the same tools that were employed by Oh-I and colleagues [2] found a 
signal peptide in the N-terminal, followed by the NLP region flanked by signature 
sequences representing proprotein convertase cleavage sites. The presence of these key 
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processing sites, which were used to discover nesfatin-1, suggests that there is a very 
strong possibility of NLP being processed from NUCB1. The mid-segment composed of 
30 amino acids is designated as the bioactive core of nesfatin-1 [176]. We found that the 
NLP is highly similar to nesfatin-1, and there is a greater degree of identity within the M30 
region of nesfatin-1 and NLP (76.6%). Twenty three amino acids in the M30 region are 
conserved (identical) between mouse nesfatin-1 and NLP. Only 7 dissimilar amino acids 
(Asp-Glu-Lys-Gln-Glu-Pro-Lys at positions 50, 51, 54, 55, 58, 64 and 72 of nesfatin-1 
replaced by His-Arg-Gln-Glu-Asn-Gly-Ala in the M30 region of NLP) were found. These 
similarities suggest that NLP, like nesfatin-1, is a biologically active peptide. 
Our in vitro studies using synthetic NLP is in agreement with this notion. Short-
term exposure of MIN6 cells cultured in 25 mM glucose to synthetic NLP at 10 and 100 
nM resulted in an increase in preproinsulin mRNA expression and insulin release into the 
media. These results indicate that NLP is insulinotropic. The stimulatory effect was absent 
at a higher concentration (1000 nM) of NLP. This could be due to the desensitization or 
downregulation of the receptor(s) through which nesfatin-1 and NLP elicits its effects. 
There are some suggestions that nesfatin-1 effects are mediated via one or more G-
protein coupled receptors (GPCRs) [180], but the identity of nesfatin-1 receptors remains 
unknown. Recently, GPCR12 family was proposed as nesfatin-1 receptors [182]. It is 
possible that NLP also mediates its insulinotropic effects through the same or related 
nesfatin-1 receptors. In a separate study, we did not find any insulinotropic effects for 
NLP on MIN6 cells cultured at 2 mM or 5.6 mM glucose media (data not shown). This 
result shows that NLP stimulates insulin only at high glucose concentrations, but not at 
hypo- or normoglycemic conditions. Also, in vitro studies using the scrambled peptide to 
NLP suggests that the specific sequence of 77 amino acid is critical for the insulinotropic 
action of NLP. The data clearly shows that both 10 and 100 nM of scrambled peptide to 
NLP could not elicit the same response in preproinsulin expression and insulin secretion 
when compared to similar doses of NLP. When comparing the data from the scrambled 
peptide and NLP, the basal insulin from controls in scrambled peptide study were lower 
(25-30 ng/mL) than in the initial NLP study. This can be attributed to the difference in the 
MIN6 confluency between both independent studies. 
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This research also indicates that the endocrine pancreas is an abundant source of 
NUCB1. The expression of NUCB1 mRNA was detected in both mice pancreas and MIN6 
cells. Specifically, NUCB1 was found to be co-localized with insulin immunopositive cells 
in pancreatic islets. This is in line with the previous immunohistochemical studies by 
Williams et al., [219] which shows NUCB1-IR to be distributed with insulin immunopositive 
cells. They also found NUCB1 to be co-localized with golgi apparatus protein, giatin, 
shedding light on its subcellular localization in pancreas. This indicates that the pancreas, 
especially the endocrine pancreas is a source of NUCB1 and NLP. As a confirmation to 
this at the protein level, immunocytochemical studies show clear co-localization of 
NUCB1 with insulin in cultured MIN6 cells and islet beta cells of mice. Preliminary results 
evaluating the endogenous NUCB1 protein expression in major peripheral tissues in 
response to feed availability shows a significant increase in liver NUCB1 expression 
under fasted state. Previous results have shown a similar 5 to 6 fold increase in liver 
NUCB2 mRNA expression in fasted goldfish [180]. Also, nesfatin-1 treatment in ad libitum 
fed rats increased phosphoenolpyruvate carboxykinase 1 (PEPCK1) and gluose-6-
phosphatase (G6P) mRNA expression in liver [13]. Both PEPCK1 and G6P plays crucial 
role in hepatic gluconeogenesis. The increase can be attributed to the inhibition of 
caspase mediated cleavage of NUCB1 [244]. The liver is actively involved in 
gluconeogenesis under fasted state compensating for the lack of glucose. 
Glyceraldehyde-3-phosphate (G3P) which is an important intermediate in the pathway is 
expected to be higher during gluconeogenesis. Previous studies have also established a 
direct inhibitory role of G3P on caspases [245]. This is physiologically relevant as 
cleavage site for caspases is highly conserved between both NUCB1 and NUCB2 [244]. 
Whether or not NUCB1 or NLP regulates the expression of enzymes involved in hepatic 
gluconeogenesis, be it G6P, PEPCK1 or G3P requires further assessment. Contrastingly, 
no changes in response to feed availability were observed in stomach and pancreas. 
Western blots were unable to capture the presence of a processed peptide i.e. NLP. This 
can be attributed to the specificity of the antibody used. Immunoprecipitation of protein 
antigen from media and plasma samples using a highly specific antibody targeting the 
NLP region in NUCB1 should provide a clearer picture on NLP secretion. Also, 
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assessment of the levels of NLP in conditioned culture media in vitro and its levels in 
circulation in vivo using a custom ELISA warrants consideration.  
Subcutaneous infusion of 100 µg/kg body weight NLP in mice had no effect on 
feed intake. This study needs repetition to test additional doses of NLP, and to determine 
whole body energy homeostasis using a metabolic cage system. The bioactive core of 
nesfatin-1 containing 30 amino acids was attributed to its anorexigenic action as neither 
the N-terminal segment nor the C-terminal segment increased central POMC and c-Fos 
expression upon peripheral or I.C.V administration in mice [9]. Interestingly, the mid 
segment of nesfatin-1 has high homology to the active site of AgRP and α-MSH. 
Subsequent studies on the activities of mutant molecules by replacing mid-segment sites 
with alanine clearly showed that the similarity to AgRP active site is critical for a peptide 
to be anorexigenic [182]. Considering that NUCB1 is a secreted protein, NLP presumably 
could elicit its biological functions in an endocrine manner. The presence of nesfatin-1 
and NUCB1 in pancreatic islet beta cells suggests possible local effects, in addition to the 
endocrine effects for NLP in islet hormone secretion. In conclusion, these results provide 
the first set of information on NLP as an endogenous insulinotropic peptide encoded in 
NUCB1. Future studies, examining NLP under normal and atypical physiological 
conditions in vivo, especially in diabetes and obesity, and mechanism of action of NLP 
warrant consideration. 
3.5. CONCLUSIONS 
 This research provides the first set of evidence for a NUCB1 encoded biologically 
active nesfatin-1-like peptide (NLP). We characterized the expression of NUCB1 mRNA 
and NUCB1 immunoreactivity in MIN6 cells and mouse pancreas. We found NUCB1 to 
be co-localized with insulin immunopositive cells in pancreas and MIN6 cells. In silico 
analysis of NUCB1 amino acid sequence detected a potential prohormone convertase 
cleavage site. Given the fact that both MIN6 cells and pancreatic islets have the 
appropriate enzyme machinery (prohormone convertases) indicates that NUCB1-
encoded NLP could be secreted. Since both nesfatin-1 and NLP were highly similar we 
tested insulinotropic action of NLP by treatment of MIN6 cells dose-dependently with 
exogenous NLP. NLP upregulated preproinsulin mRNA expression and insulin secretion. 
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Although, MIN6 cells are highly representative of pancreatic β cells, the consistency of 
the current results needs to be tested in the primary cells of pancreatic islets by islet 
isolation. By static incubation studies of cells with a peptide scramble of NLP, we showed 
that the predicted 77 amino acid sequence arrangement of NLP might be critical for its 
insulinotropic action in vitro. Also since nesfatin-1 was reported to be an anorexigenic 
peptide capable of inducing satiety and reducing dark phase feed intake and since NLP 
was highly similar to nesfatin-1, we tested the potential appetite regulatory function of 
NLP on C57BL/6J mice and found that subcutaneous infusion of 100 µg/Kg body weight 
NLP had no effect on both dark and light phase feed intake. A future study evaluating the 
effect of I.C.V and I.P injection of NLP on feed intake will provide a more complete picture. 
We also performed studies to evaluate the changes in the endogenous expression levels 
of NUCB1 with respect to feed availability. Preliminary results from Western blots show a 
significant increase in NUCB1 protein expression in liver under fasted state. However, no 
changes in the protein expression in stomach and pancreas were observed. The Western 
blot analysis for the current chapter is currently under progress and will be completed 
soon. Overall, findings in the current chapter shed light on a NUCB1 encoded bioactive 
NLP. The results in this chapter iterate the insulinotropic action of NLP, attributing its 
biological action to its specific 77 amino acid sequence. This project has also opened a 
variety of avenues to explore to reconfirm and evaluate the current hypothesis, and some 
future extensions are discussed in chapter 4. 
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CHAPTER 4 
INTEGRATION OF FINDINGS AND FUTURE DIRECTIONS 
4.1. INTEGRATION OF FINDINGS 
 This thesis research is novel and highly original, and was aimed to extend our 
current knowledge on nesfatin-1 biology. It resulted in two major discoveries: 1. nesatin-
1 presence in enteroendocrine cells, and its modulation of intestinal hormones, and 2. 
identification of an insulinotropic, nesfatin-1 like peptide encoded in NUCB1. This section 
of the thesis will address some of the implications of the results obtained, limitations of 
the research and future directions. 
The focus of chapter 2 in this thesis was to evaluate the presence of endogenous 
NUCB2/nesfatin-1 in mouse intestine and to study the effects of nesfatin-1 administration 
in vitro in mouse intestinal cell line, STC-1 and in vivo in mouse intestine. NUCB2 mRNA 
was present in STC-1 cells. The result was highly indicative that intestinal 
enteroendocrine cells could be a source of endogenous nesfatin-1 in vivo, possibly 
contributing to the post-meal increase reported previously [11]. This also highlights the 
utility of STC-1 cells for studying nesfatin-1 biology in addition to study the secretion 
kinetics of major enteric hormones GLP-1, GIP, PYY and CCK.  This research also 
considered the expression of NUCB2 in ad libitum fed mouse intestine. Supporting the 
previous evidences [15, 193, 246], NUCB2/nesfatin-1 immunoreactive cells were found 
in mouse intestine and were predominantly localized in the crypts of the intestinal villi, 
Brunner’s glands and in the blood vessels surrounding the connective tissue. Besides 
being a crucial site for nutrient absorption, intestine is a major endocrine organ secreting 
hormones that modulate energy metabolism and glucose homeostasis. Nesfatin-1 was 
found colocalized with a number of enteric hormones including GLP-1, GIP, PYY and 
CCK. The co-presence of these hormones in the same cells that secrete important 
metabolic hormones implies its significance in physiological roles, especially the 
regulation of whole body energy homeostasis and insulin secretion by nesfatin-1. It also 
raises the possibility that nesfatin-1 might have local autocrine or paracrine effects in 
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regulating the secretion of intestinal hormones. Whether nesfatin-1 is stored in the same 
secretory vesicles, and is secreted with other hormones remain unknown. 
The presence of nesfatin-1 immunoreactivity in intestine raised an important 
question: Does nesfatin-1 modulate intestinal hormone secretion? Immunohistochemical 
staining of C57BL/6J small and large intestinal sections showed NUCB2/nesfatin-1 to be 
co-localized with GLP-1, GIP, PYY and CCK immunopositive cells. Subsequent in vitro 
studies on STC-1 cells showed a significant dose-dependent upregulation of GLP-1, GIP, 
CCK, and downregulation of PYY mRNA expression and secretion. These results are 
highly suggestive that nesfatin-1 has the potential to activate insulinotropic intestinal 
hormones and suppresses insulinostatic hormones of intestinal origin, to modulate insulin 
secretion. A major limitation of this approach is that the studies were conducted only in 
vitro, and that again used immortalized cell lines. While the results obtained are 
conclusive, it is important to determine whether biological actions of nesfatin-1 found in 
vitro also exist in vivo. The in vivo studies evaluating the relative levels of intestinal 
hormones in circulation in response to subcutaneous osmotic pump infusion of 100 µg/kg 
body weight nesfatin-1 in mice was indeed conducted. However, some technical 
challenges prevented us from obtaining conclusive data on enteric hormone secretion in 
this study. The tissues collected will now be evaluated for relative mRNA and protein 
expression of enteric hormones using RT-qPCR and Western blotting. This work also 
requires further enquiries on the mechanistic aspects of nesfatin-1’s action in intestine 
including the nature of its receptors, chapter 2 details its presence in the intestine, 
establishing enteroendocrine cells as a source for endogenous nesfatin-1. It also affirmed 
that nesfatin-1 indeed modulates secretion of intestinal hormones in vitro, paving way for 
a thought that an indirect route of its insulinotropic action is possibly by stimulating other 
enteric insulinotropins and inhibiting enteric insulinostatins. Additional studies using 
enteric hormone knockout mice will be a great tool to determine whether nesfatin-1 action 
on other insulin regulatory hormones is critical for its insulinotropic actions. To the best of 
our knowledge, this remains the first report on direct actions of nesfatin-1 in modulating 
enteric hormones (Figure 4.1). This finding adds an additional function, intestinal 
hormone regulation, to the growing list of biological actions of nesfatin-1 (Figure 4.1). 
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Figure 4.1. A summary figure depicting the multi-functional stimulatory and inhibitory 
roles of nesfatin-1 reported. Chapter 2 extends this by the identification of a direct role for 
nesfatin-1 in regulating intestinal hormone secretion. 
The findings elaborated in chapter 2 are in line with our hypothesis. Further studies 
are required to reconfirm and clarify the role of nesfatin-1 in regulating intestinal hormone 
secretion. Specifically, the immunoassays took into account total GLP-1 and GIP content. 
Therefore, a separate assay evaluating the secretion of levels of active forms of both the 
peptides (GLP-1 (7-37) and GIP (1-42) is warranted along with the use of DDP-IV 
inhibitors. Similarly, whether or not nesfatin-1 modulates the secretion of CCK-8 and 
CCK-33, which are two bioactive forms of CCK in circulation also requires clarification. 
With respect to the mRNA expression data on GLP-1, the proglucagon gene besides 
GLP-1 also encodes GLP-2 and oxyntomodulin. Although the primer used for the study 
targets the GLP-1 encoding region of the proglucagon gene, yet a Western blot evaluating 
the changes in the GLP-1 protein expression in response to dose-dependent treatment 
of nesfatin-1 is necessary for research rigor. Results from the in vivo studies including the 
changes in circulating levels of intestinal hormones in response to subcutaneous, I.P or 
I.C.V administration of nesfatin-1 will provide a complete picture on the nature of nesfatin-
1 modulation of enteric hormones. Some of the possible future directions for this chapter 
are outlined later in this chapter. 
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At the time when we initiated research in chapter 3, no information existed about 
a NUCB1 encoded bioactive peptide. We detected both NUCB1 mRNA expression and 
immunoreactivity in pancreatic islets of C57BL/6J mice and in mouse insulinoma cells 
MIN6. This reaffirms that endocrine pancreas is an abundant source of endogenous 
NUCB1. Also, NUCB1 immunoreactivity was co-localized with insulin immunopositive 
cells in islets, suggesting that NUCB1 or an encoded peptide could modulate insulin 
secretion. Similar to the characterization of nesfatin-1 from NUCB2 [9], we hypothesized 
that NUCB1 encodes a bioactive nesfatin-1-like peptide (NLP) that could be secreted. In 
silico analysis of NUCB1 amino acid sequence convincingly showed the presence of a 77 
amino acid NLP. We have previously demonstrated that both islets and MIN6 cells 
express NUCB2/nesfatin-1 and that nesfatin-1 dose-dependently stimulates GSIS [5]. 
Owing to its high similarity to nesfatin-1, especially high identity (76.6%) in the 30 amino 
acid mid segment region (the bioactive core of nesfatin-1), we hypothesized that NLP 
could have an insulinotropic action similar to nesfatin-1. Testing this hypothesis via in vitro 
studies on MIN6 cells cultured under hyperglycemic conditions (25 mM glucose), we 
demonstrated that short-term exposure to exogenous NLP stimulates preproinsulin 
mRNA expression and insulin secretion at 10 and 100 nM doses. To confirm the specific 
77 amino acid sequence of NLP is critical for its bioactivity and to test whether any peptide 
that shares the same amino acid length but dissimilar amino acids could also elicit the 
same response as NLP, we treated MIN6 cells with a scrambled peptide to NLP at doses 
that were found effective with NLP (10 and 100 nM). The results from the scrambled 
peptide study clearly demonstrated that the specific sequence of 77 amino acids is 
required for NLP’s action on insulin secretion in vitro. We then quantified the endogenous 
levels of NUCB1 expression in response to feed availability in mice. We found a significant 
increase in NUCB1 expression in fasted mice liver and found no changes in pancreas 
and stomach. Further, we tested whether NLP modulates appetite similar to nesfatin-1, 
by subcutaneously infusing 100 µg/kg body weight NLP in C57BL/6J mice. Results from 
this study demonstrated that NLP, at the dose tested and mode of administration has no 
effect on both light and dark phase feed intake. 
The findings described in chapter 3 are supportive of our hypothesis. However, 
whether an endogenous NLP exists still remains inconclusive. Future efforts should focus 
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on addressing this critical question, and identify the processed endogenous peptide from 
NUCB1. NLP also requires rigorous set of studies designed to evaluate its insulinotropic 
action in vivo, especially under atypical physiological conditions like T2D, obesity and in 
islets isolated from perfused mice pancreas (primary cell line studies). This is necessary 
because when compared to nesfatin-1, NLP is insulinotropic at higher doses and the 
increase in insulin secretion is modest. Also, under both in vitro and in vivo conditions, 
the basal levels of NLP in culture media and in circulation remain to be elucidated by 
means of a dedicated immunoassay (ELISA or RIA). This will aid in better design for 
future studies evaluating the dose-dependency of NLP in any given biological system and 
also to affirm that NLP indeed is secreted in vivo.  Similar to nesfatin-1, the N-, C- and 
mid-segment of NLP could be fragmented by incubation of peptide with prohormone 
convertases and caspases, with each fragment being tested for insulinotropic action and 
satiety. A few possible future directions for this chapter are described in section 4.2 below. 
A preliminary conclusion is that both NUCB1 encoded NLP, and NUCB2 encoded 
nesfatin-1 modulate insulin secretion in mammals. This insulinotropic effect is direct. Our 
results, especially from chapter 2, trigger a new possibility where nesfatin-1 and/or NLP 
act directly on intestinal hormones, and this modulation of intestinal hormones indirectly 
mediates its insulinotropic action (Figure 4.2). 
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Figure 4.2. A schematic representation depicting the overall conclusion of chapter 2 and 
3. Nesfatin-1 encoded by NUCB2 is present in intestine and modulates major intestinal 
hormones (GLP-1, GIP, CCK and PYY). A nesfatin-1-like peptide encoded by NUCB1 
stimulates insulin secretion in vitro in MIN6 cells and the same response is absent upon 
administration of an amino acid scramble to NLP. This diagram concludes that two known 
nucleobindins (NUCB1 and NUCB2) modulate insulin secretion. While NUCB2 encoded 
nesfatin-1 stimulates insulin secretion via a direct action on pancreatic islets and indirectly 
via stimulation/inhibition of insulinotropic/insulinostatic intestinal hormones, NUCB1 
encoded NLP modulates insulin secretion by a direct action in vitro. 
4.2. FUTURE DIRECTIONS 
1. A time-dependent study of nesfatin-1 doses on enteric hormone secretion in 
STC-1 cells: One limitation of the current study is that it considered only a single time 
point i.e. 1 hour incubation. In a future study, a dose of nesfatin-1 effective in modulating 
enteric hormone secretion should be tested at 15, 30, 45 minutes and 1.5, 2 hours to 
determine whether the effects of exogenous nesfatin-1 reported in this chapter continues 
to exist for both longer and shorter durations. Also, new and previous data generated will 
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be normalized using two or more reference genes (β-Actin, GAPDH and α-tubulin) for 
consistency and rigor. 
2. Determine the serum levels of enteric hormones post intraperitoneal injection of 
nesfatin-1: While the changes in the serum levels of enteric hormones in response to 24 
hour osmotic pump infusion of nesfatin-1 are currently being tested, whether these effects 
are consistent in response to an I.P injection of nesfatin-1 remains to be seen. 
Immunoassays for circulating levels and Western blot for changes in the protein 
expression will be carried out in the tissues collected. 
3. Absence of endogenous nesfatin-1: The studies explored the effects of exogenous 
nesfatin-1 on mice enteric hormone secretion in vivo and the role of nesfatin-1 treatment 
in STC-1 cells in vitro. However, these studies do not help understanding whether 
endogenous nesfatin-1 is critical for this action. Intestine specific NUCB2 knockout and 
knockdown strategies should be used to delete or attenuate endogenous nesfatin-1, and 
determine how the secretion levels of intestinal hormones in the absence of this 
regulatory peptide are, with respect to feed availability. This will provide crucial insights 
and start points for studying the mechanism of nesfatin-1 action on intestinal hormones. 
4. Endogenous Expression of NLP – Changes based on Feed Availability: While we 
are currently focusing on the endogenous NUCB1 expression in peripheral tissues under 
feed availability, we so far have met with moderate success in capturing the band for the 
processed NLP peptide. To negate this, immunoprecipitation using a highly NLP specific 
antibody is helpful. The study will also ascertain whether or not endogenous NUCB1/NLP 
has variable tissue specific expression under feed deprivation. 
5. Determine the levels of NLP in circulation: While the current studies tested the 
changes in insulin secretion upon dose-dependent treatment of NLP in MIN6 cells, 
evaluating its level in circulation and particularly under atypical physiological conditions 
like diabetes and obesity is necessary. Also, these studies will iterate that NLP is indeed 
a secreted protein in vivo. 
6. Time-dependent Study of NLP Doses on Insulin Secretion: The current study 
design have considered only a single time point i.e. 1 hour. In a future study, an effective 
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dose of NLP capable of stimulating insulin secretion should be tested at different time 
points. This study is crucial when addressing a novel peptide like NLP, as it helps 
determining the efficacy of the peptide and its kinetics. 
7. Biological Actions of NLP: The studies in the thesis elucidated NLP to be an 
insulinotropic peptide similar to nesfatin-1. However, whether NLP and nesfatin-1 share 
their biological actions pertaining to energy balance remains to be studied. Studies 
evaluating IPGTT, ITT, OGTT and metabolic parameters (using CLAMS) of NLP infused 
mice will provide insights on its regulation of glucose and energy homeostasis similar to 
nesfatin-1. Also, assessing whether or not NLP modulates intestinal hormone secretion 
similar to nesfatin-1, opens up new possibilities for its unknown biological actions.  
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